{
    "abstract": "Lassa fever remains the most imported viral haemorrhagic fever in Europe and is responsible for 5000 deaths per year throughout Western Africa. There is no vaccine and treatment is often ineffective. We have developed a vaccine based on modified Vaccinia Ankara expressing the nucleoprotein from Lassa virus (MVALassaNP). This study investigated the immunogenicity (in mice) and efficacy (in guinea pigs) of the MVALassaNP vaccine as a prime/boost or single vaccination regime. ELISA and ELISpot assays confirmed humoral and T-cell immunity following both a prime and prime/boost vaccination, with the prime/boost regime producing a statistically increased response compared to a prime only vaccine (P < 0.0001). The vaccine offered protection in guinea pigs against disease manifestations after challenge with virulent Lassa virus. Clinical signs, weight loss and temperature increases were observed in all animals receiving a control MVA vaccine, after challenge with Lassa virus. In contrast, no clinical signs, fever or weight loss were observed in any of the MVALassaNP vaccinated animals demonstrating that both a single immunisation, and prime/boost regime confer protection against disease progression. In conclusion, the MVALassaNP vaccine candidate elicits an immune response, demonstrates efficacy against Lassa virus disease and is suitable for further preclinical and clinical development.",
    "bib_entries": {
        "b0005": {
            "authors": [
                {
                    "first": "Nadezhda E.",
                    "initial": "N.E.",
                    "last": "Yun"
                },
                {
                    "first": "David H.",
                    "initial": "D.H.",
                    "last": "Walker"
                }
            ],
            "doi": "10.3390/v4102031",
            "firstpage": "2031",
            "issn": "19994915",
            "lastpage": "2048",
            "pmid": "23202452",
            "pub_year": 2012,
            "title": "Pathogenesis of lassa fever",
            "volume": "4"
        },
        "b0010": null,
        "b0015": {
            "authors": [
                {
                    "first": "S. P.",
                    "initial": "S.P.",
                    "last": "Fisher-Hoch"
                },
                {
                    "first": "O.",
                    "initial": "O.",
                    "last": "Tomori"
                },
                {
                    "first": "A.",
                    "initial": "A.",
                    "last": "Nasidi"
                },
                {
                    "first": "G. I.",
                    "initial": "G.I.",
                    "last": "Perez-Oronoz"
                },
                {
                    "first": "Y.",
                    "initial": "Y.",
                    "last": "Fakile"
                },
                {
                    "first": "L.",
                    "initial": "L.",
                    "last": "Hutwagner"
                },
                {
                    "first": "J. B.",
                    "initial": "J.B.",
                    "last": "Mccormick"
                }
            ],
            "doi": "10.1136/bmj.311.7009.857",
            "firstpage": "857",
            "issn": "09598138",
            "pmid": "7580496",
            "pub_year": 1995,
            "title": "Review of cases of nosocomial Lassa fever in Nigeria: The high price of poor medical practice",
            "volume": "311"
        },
        "b0020": {
            "authors": [
                {
                    "first": "M. E.",
                    "initial": "M.E.",
                    "last": "Price"
                },
                {
                    "first": "S. P.",
                    "initial": "S.P.",
                    "last": "Fisher-Hoch"
                },
                {
                    "first": "R. B.",
                    "initial": "R.B.",
                    "last": "Craven"
                },
                {
                    "first": "J. B.",
                    "initial": "J.B.",
                    "last": "McCormick"
                }
            ],
            "doi": "10.1136/bmj.297.6648.584",
            "firstpage": "584",
            "issn": "02670623",
            "lastpage": "587",
            "pmid": "3139220",
            "pub_year": 1988,
            "title": "A prospective study of maternal and fetal outcome in acute Lassa fever infection during pregnancy",
            "volume": "297"
        },
        "b0025": {
            "authors": [
                {
                    "first": "J.",
                    "initial": "J.",
                    "last": "Salazar-Bravo"
                },
                {
                    "first": "L. A.",
                    "initial": "L.A.",
                    "last": "Ruedas"
                },
                {
                    "first": "T. L.",
                    "initial": "T.L.",
                    "last": "Yates"
                }
            ],
            "firstpage": "25",
            "issn": "0070217X",
            "lastpage": "63",
            "pmid": "11987807",
            "pub_year": 2002,
            "title": "Mammalian reservoirs of arenaviruses",
            "volume": "262"
        },
        "b0030": {
            "authors": [
                {
                    "first": "J.",
                    "initial": "J.",
                    "last": "Ter Meulen"
                },
                {
                    "first": "I.",
                    "initial": "I.",
                    "last": "Lukashevich"
                },
                {
                    "first": "K.",
                    "initial": "K.",
                    "last": "Sidibe"
                },
                {
                    "first": "A.",
                    "initial": "A.",
                    "last": "Inapogui"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Marx"
                },
                {
                    "first": "A.",
                    "initial": "A.",
                    "last": "Dorlemann"
                },
                {
                    "first": "M. L.",
                    "initial": "M.L.",
                    "last": "Yansane"
                },
                {
                    "first": "K.",
                    "initial": "K.",
                    "last": "Koulemou"
                },
                {
                    "first": "J.",
                    "initial": "J.",
                    "last": "Chang-Claude"
                },
                {
                    "first": "H.",
                    "initial": "H.",
                    "last": "Schmitz"
                }
            ],
            "firstpage": "661",
            "issn": "00029637",
            "lastpage": "666",
            "pmid": "9025695",
            "pub_year": 1996,
            "title": "Hunting of peridomestic rodents and consumption of their meat as possible risk factors for rodent-to-human transmission of lassa virus in the Republic of Guinea",
            "volume": "55"
        },
        "b0035": {
            "authors": [
                {
                    "first": "Sheli R.",
                    "initial": "S.R.",
                    "last": "Radoshitzky"
                },
                {
                    "first": "Y\u012bm\u00edng",
                    "initial": "Y.",
                    "last": "B\u00e0o"
                },
                {
                    "first": "Michael J.",
                    "initial": "M.J.",
                    "last": "Buchmeier"
                },
                {
                    "first": "R\u00e9mi N.",
                    "initial": "R.N.",
                    "last": "Charrel"
                },
                {
                    "first": "Anna N.",
                    "initial": "A.N.",
                    "last": "Clawson"
                },
                {
                    "first": "Christopher S.",
                    "initial": "C.S.",
                    "last": "Clegg"
                },
                {
                    "first": "Joseph L.",
                    "initial": "J.L.",
                    "last": "DeRisi"
                },
                {
                    "first": "S\u00e9bastien",
                    "initial": "S.",
                    "last": "Emonet"
                },
                {
                    "first": "Jean Paul",
                    "initial": "J.P.",
                    "last": "Gonzalez"
                },
                {
                    "first": "Jens H.",
                    "initial": "J.H.",
                    "last": "Kuhn"
                },
                {
                    "first": "Igor S.",
                    "initial": "I.S.",
                    "last": "Lukashevich"
                },
                {
                    "first": "Clarence J.",
                    "initial": "C.J.",
                    "last": "Peters"
                },
                {
                    "first": "Victor",
                    "initial": "V.",
                    "last": "Romanowski"
                },
                {
                    "first": "Maria S.",
                    "initial": "M.S.",
                    "last": "Salvato"
                },
                {
                    "first": "Mark D.",
                    "initial": "M.D.",
                    "last": "Stenglein"
                },
                {
                    "first": "Juan C.arlos",
                    "initial": "J.C.a.",
                    "last": "de la Torre"
                }
            ],
            "doi": "10.1007/s00705-015-2418-y",
            "firstpage": "1851",
            "issn": "14328798",
            "lastpage": "1874",
            "pmid": "25935216",
            "pub_year": 2015,
            "title": "Past, present, and future of arenavirus taxonomy",
            "volume": "160"
        },
        "b0040": {
            "authors": [
                {
                    "first": "Michael D.",
                    "initial": "M.D.",
                    "last": "Bowen"
                },
                {
                    "first": "Pierre E.",
                    "initial": "P.E.",
                    "last": "Rollin"
                },
                {
                    "first": "Thomas G.",
                    "initial": "T.G.",
                    "last": "Ksiazek"
                },
                {
                    "first": "Heather L.",
                    "initial": "H.L.",
                    "last": "Hustad"
                },
                {
                    "first": "Daniel G.",
                    "initial": "D.G.",
                    "last": "Bausch"
                },
                {
                    "first": "Austin H.",
                    "initial": "A.H.",
                    "last": "Demby"
                },
                {
                    "first": "Mary D.",
                    "initial": "M.D.",
                    "last": "Bajani"
                },
                {
                    "first": "Clarence J.",
                    "initial": "C.J.",
                    "last": "Peters"
                },
                {
                    "first": "Stuart T.",
                    "initial": "S.T.",
                    "last": "Nichol"
                }
            ],
            "doi": "10.1128/JVI.74.15.6992-7004.2000",
            "firstpage": "6992",
            "issn": "0022538X",
            "lastpage": "7004",
            "pmid": "10888638",
            "pub_year": 2000,
            "title": "Genetic diversity among Lassa virus strains",
            "volume": "74"
        },
        "b0045": null,
        "b0050": {
            "authors": [
                {
                    "first": "Luis M.",
                    "initial": "L.M.",
                    "last": "Branco"
                },
                {
                    "first": "Jessica N.",
                    "initial": "J.N.",
                    "last": "Grove"
                },
                {
                    "first": "Frederick J.",
                    "initial": "F.J.",
                    "last": "Geske"
                },
                {
                    "first": "Matt L.",
                    "initial": "M.L.",
                    "last": "Boisen"
                },
                {
                    "first": "Ivana J.",
                    "initial": "I.J.",
                    "last": "Muncy"
                },
                {
                    "first": "Susan A.",
                    "initial": "S.A.",
                    "last": "Magliato"
                },
                {
                    "first": "Lee A.",
                    "initial": "L.A.",
                    "last": "Henderson"
                },
                {
                    "first": "Randal J.",
                    "initial": "R.J.",
                    "last": "Schoepp"
                },
                {
                    "first": "Kathleen A.",
                    "initial": "K.A.",
                    "last": "Cashman"
                },
                {
                    "first": "Lisa E.",
                    "initial": "L.E.",
                    "last": "Hensley"
                },
                {
                    "first": "Robert F.",
                    "initial": "R.F.",
                    "last": "Garry"
                }
            ],
            "doi": "10.1186/1743-422X-7-279",
            "issn": "1743422X",
            "pmid": "20961433",
            "pub_year": 2010,
            "title": "Lassa virus-like particles displaying all major immunological determinants as a vaccine candidate for Lassa hemorrhagic fever",
            "volume": "7"
        },
        "b0055": {
            "authors": [
                {
                    "first": "Maria P.",
                    "initial": "M.P.",
                    "last": "Rodriguez-Carreno"
                },
                {
                    "first": "Michael S.",
                    "initial": "M.S.",
                    "last": "Nelson"
                },
                {
                    "first": "Jason",
                    "initial": "J.",
                    "last": "Botten"
                },
                {
                    "first": "Kim",
                    "initial": "K.",
                    "last": "Smith-Nixon"
                },
                {
                    "first": "Michael J.",
                    "initial": "M.J.",
                    "last": "Buchmeier"
                },
                {
                    "first": "J. Lindsay",
                    "initial": "J.L.",
                    "last": "Whitton"
                }
            ],
            "doi": "10.1016/j.virol.2005.01.019",
            "firstpage": "87",
            "issn": "00426822",
            "lastpage": "98",
            "pmid": "15823608",
            "pub_year": 2005,
            "title": "Evaluating the immunogenicity and protective efficacy of a DNA vaccine encoding Lassa virus nucleoprotein",
            "volume": "335"
        },
        "b0060": {
            "authors": [
                {
                    "first": "Igor S.",
                    "initial": "I.S.",
                    "last": "Lukashevich"
                },
                {
                    "first": "Ricardo",
                    "initial": "R.",
                    "last": "Carrion"
                },
                {
                    "first": "Maria S.",
                    "initial": "M.S.",
                    "last": "Salvato"
                },
                {
                    "first": "Keith",
                    "initial": "K.",
                    "last": "Mansfield"
                },
                {
                    "first": "Kathleen",
                    "initial": "K.",
                    "last": "Brasky"
                },
                {
                    "first": "Juan",
                    "initial": "J.",
                    "last": "Zapata"
                },
                {
                    "first": "Cristiana",
                    "initial": "C.",
                    "last": "Cairo"
                },
                {
                    "first": "Marco",
                    "initial": "M.",
                    "last": "Goicochea"
                },
                {
                    "first": "Gia E.",
                    "initial": "G.E.",
                    "last": "Hoosien"
                },
                {
                    "first": "Anysha",
                    "initial": "A.",
                    "last": "Ticer"
                },
                {
                    "first": "Joseph",
                    "initial": "J.",
                    "last": "Bryant"
                },
                {
                    "first": "Harry",
                    "initial": "H.",
                    "last": "Davis"
                },
                {
                    "first": "Rasha",
                    "initial": "R.",
                    "last": "Hammamieh"
                },
                {
                    "first": "Maria",
                    "initial": "M.",
                    "last": "Mayda"
                },
                {
                    "first": "Marti",
                    "initial": "M.",
                    "last": "Jett"
                },
                {
                    "first": "Jean",
                    "initial": "J.",
                    "last": "Patterson"
                }
            ],
            "doi": "10.1016/j.vaccine.2008.07.057",
            "firstpage": "5246",
            "issn": "0264410X",
            "lastpage": "5254",
            "pmid": "18692539",
            "pub_year": 2008,
            "title": "Safety, immunogenicity, and efficacy of the ML29 reassortant vaccine for Lassa fever in small non-human primates",
            "volume": "26"
        },
        "b0065": {
            "authors": [
                {
                    "first": "Xiaohong",
                    "initial": "X.",
                    "last": "Jiang"
                },
                {
                    "first": "Tim J.",
                    "initial": "T.J.",
                    "last": "Dalebout"
                },
                {
                    "first": "Peter J.",
                    "initial": "P.J.",
                    "last": "Bredenbeek"
                },
                {
                    "first": "Ricardo",
                    "initial": "R.",
                    "last": "Carrion"
                },
                {
                    "first": "Kathleen",
                    "initial": "K.",
                    "last": "Brasky"
                },
                {
                    "first": "Jean",
                    "initial": "J.",
                    "last": "Patterson"
                },
                {
                    "first": "Marco",
                    "initial": "M.",
                    "last": "Goicochea"
                },
                {
                    "first": "Joseph",
                    "initial": "J.",
                    "last": "Bryant"
                },
                {
                    "first": "Maria S.",
                    "initial": "M.S.",
                    "last": "Salvato"
                },
                {
                    "first": "Igor S.",
                    "initial": "I.S.",
                    "last": "Lukashevich"
                }
            ],
            "doi": "10.1016/j.vaccine.2010.11.079",
            "firstpage": "1248",
            "issn": "0264410X",
            "lastpage": "1257",
            "pmid": "21145373",
            "pub_year": 2011,
            "title": "Yellow fever 17D-vectored vaccines expressing Lassa virus GP1 and GP2 glycoproteins provide protection against fatal disease in guinea pigs",
            "volume": "29"
        },
        "b0070": {
            "authors": [
                {
                    "first": "J. C.S.",
                    "initial": "J.C.S.",
                    "last": "Clegg"
                },
                {
                    "first": "G.",
                    "initial": "G.",
                    "last": "Lloyd"
                }
            ],
            "doi": "10.1016/S0140-6736(87)90767-7",
            "firstpage": "186",
            "issn": "01406736",
            "lastpage": "188",
            "pmid": "2885642",
            "pub_year": 1987,
            "title": "VACCINIA RECOMBINANT EXPRESSING LASSA-VIRUS INTERNAL NUCLEOCAPSID PROTEIN PROTECTS GUINEAPIGS AGAINST LASSA FEVER",
            "volume": "330"
        },
        "b0075": {
            "authors": [
                {
                    "first": "Hoai J.",
                    "initial": "H.J.",
                    "last": "Hallam"
                },
                {
                    "first": "Steven",
                    "initial": "S.",
                    "last": "Hallam"
                },
                {
                    "first": "Sergio E.",
                    "initial": "S.E.",
                    "last": "Rodriguez"
                },
                {
                    "first": "Alan D.T.",
                    "initial": "A.D.T.",
                    "last": "Barrett"
                },
                {
                    "first": "David W.C.",
                    "initial": "D.W.C.",
                    "last": "Beasley"
                },
                {
                    "first": "Arlene",
                    "initial": "A.",
                    "last": "Chua"
                },
                {
                    "first": "Thomas G.",
                    "initial": "T.G.",
                    "last": "Ksiazek"
                },
                {
                    "first": "Gregg N.",
                    "initial": "G.N.",
                    "last": "Milligan"
                },
                {
                    "first": "Vaseeharan",
                    "initial": "V.",
                    "last": "Sathiyamoorthy"
                },
                {
                    "first": "Lisa M.",
                    "initial": "L.M.",
                    "last": "Reece"
                }
            ],
            "doi": "10.1038/s41541-018-0049-5",
            "issn": "20590105",
            "pub_year": 2018,
            "title": "Baseline mapping of Lassa fever virology, epidemiology and vaccine research and development review-article",
            "volume": "3"
        },
        "b0080": null,
        "b0085": {
            "authors": [
                {
                    "first": "G.",
                    "initial": "G.",
                    "last": "Lloyd"
                },
                {
                    "first": "G. N.",
                    "initial": "G.N.",
                    "last": "Barber"
                },
                {
                    "first": "J. C.S.",
                    "initial": "J.C.S.",
                    "last": "Clegg"
                },
                {
                    "first": "P.",
                    "initial": "P.",
                    "last": "Kelly"
                }
            ],
            "doi": "10.1016/S0140-6736(89)91833-3",
            "firstpage": "1222",
            "issn": "01406736",
            "pmid": "2572935",
            "pub_year": 1989,
            "title": "IDENTIFICATION OF LASSA FEVER VIRUS INFECTION WITH RECOMBINANT NUCLEOCAPSID PROTEIN ANTIGEN",
            "volume": "334"
        },
        "b0090": {
            "authors": [
                {
                    "first": "S. P.",
                    "initial": "S.P.",
                    "last": "Fisher-Hoch"
                },
                {
                    "first": "L.",
                    "initial": "L.",
                    "last": "Hutwagner"
                },
                {
                    "first": "B.",
                    "initial": "B.",
                    "last": "Brown"
                },
                {
                    "first": "J. B.",
                    "initial": "J.B.",
                    "last": "McCormick"
                }
            ],
            "doi": "10.1128/JVI.74.15.6777-6783.2000",
            "firstpage": "6777",
            "issn": "0022538X",
            "lastpage": "6783",
            "pmid": "10888616",
            "pub_year": 2000,
            "title": "Effective vaccine for lassa fever",
            "volume": "74"
        },
        "b0095": {
            "authors": [
                {
                    "first": "Jan",
                    "initial": "J.",
                    "last": "Ter Meulen"
                },
                {
                    "first": "Marlis",
                    "initial": "M.",
                    "last": "Badusche"
                },
                {
                    "first": "Judith",
                    "initial": "J.",
                    "last": "Satoguina"
                },
                {
                    "first": "Thomas",
                    "initial": "T.",
                    "last": "Strecker"
                },
                {
                    "first": "Oliver",
                    "initial": "O.",
                    "last": "Lenz"
                },
                {
                    "first": "Cornelius",
                    "initial": "C.",
                    "last": "Loeliger"
                },
                {
                    "first": "Mohamed",
                    "initial": "M.",
                    "last": "Sakho"
                },
                {
                    "first": "Kekoura",
                    "initial": "K.",
                    "last": "Koulemou"
                },
                {
                    "first": "Lamine",
                    "initial": "L.",
                    "last": "Koivogui"
                },
                {
                    "first": "Achim",
                    "initial": "A.",
                    "last": "Hoerauf"
                }
            ],
            "doi": "10.1016/j.virol.2003.12.013",
            "firstpage": "134",
            "issn": "00426822",
            "lastpage": "143",
            "pmid": "15033572",
            "pub_year": 2004,
            "title": "Old and New World arenaviruses share a highly conserved epitope in the fusion domain of the glycoprotein 2, which is recognized by Lassa virus-specific human CD4+ T-cell clones",
            "volume": "321"
        },
        "b0100": {
            "authors": [
                {
                    "first": "S. P.",
                    "initial": "S.P.",
                    "last": "Fisher-Hoch"
                },
                {
                    "first": "J. B.",
                    "initial": "J.B.",
                    "last": "McCormick"
                },
                {
                    "first": "D.",
                    "initial": "D.",
                    "last": "Auperin"
                },
                {
                    "first": "B. G.",
                    "initial": "B.G.",
                    "last": "Brown"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Castor"
                },
                {
                    "first": "G.",
                    "initial": "G.",
                    "last": "Perez"
                },
                {
                    "first": "S.",
                    "initial": "S.",
                    "last": "Ruo"
                },
                {
                    "first": "A.",
                    "initial": "A.",
                    "last": "Conaty"
                },
                {
                    "first": "L.",
                    "initial": "L.",
                    "last": "Brammer"
                },
                {
                    "first": "S.",
                    "initial": "S.",
                    "last": "Bauer"
                }
            ],
            "doi": "10.1073/pnas.86.1.317",
            "firstpage": "317",
            "issn": "00278424",
            "lastpage": "321",
            "pmid": "2911575",
            "pub_year": 1989,
            "title": "Protection of rhesus monkeys from fatal Lassa fever by vaccination with a recombinant vaccinia virus containing the Lassa virus glycoprotein gene",
            "volume": "86"
        },
        "b0105": {
            "authors": [
                {
                    "first": "Thomas W.",
                    "initial": "T.W.",
                    "last": "Geisbert"
                },
                {
                    "first": "Steven",
                    "initial": "S.",
                    "last": "Jones"
                },
                {
                    "first": "Elizabeth A.",
                    "initial": "E.A.",
                    "last": "Fritz"
                },
                {
                    "first": "Amy C.",
                    "initial": "A.C.",
                    "last": "Shurtleff"
                },
                {
                    "first": "Joan B.",
                    "initial": "J.B.",
                    "last": "Geisbert"
                },
                {
                    "first": "Ryan",
                    "initial": "R.",
                    "last": "Liebscher"
                },
                {
                    "first": "Allen",
                    "initial": "A.",
                    "last": "Grolla"
                },
                {
                    "first": "Ute",
                    "initial": "U.",
                    "last": "Str\u00f6her"
                },
                {
                    "first": "Lisa",
                    "initial": "L.",
                    "last": "Fernando"
                },
                {
                    "first": "Kathleen M.",
                    "initial": "K.M.",
                    "last": "Daddario"
                },
                {
                    "first": "Mary C.",
                    "initial": "M.C.",
                    "last": "Guttieri"
                },
                {
                    "first": "Bianca R.",
                    "initial": "B.R.",
                    "last": "Moth\u00e9"
                },
                {
                    "first": "Tom",
                    "initial": "T.",
                    "last": "Larsen"
                },
                {
                    "first": "Lisa E.",
                    "initial": "L.E.",
                    "last": "Hensley"
                },
                {
                    "first": "Peter B.",
                    "initial": "P.B.",
                    "last": "Jahrling"
                },
                {
                    "first": "Heinz",
                    "initial": "H.",
                    "last": "Feldmann"
                }
            ],
            "doi": "10.1371/journal.pmed.0020183",
            "firstpage": "0537",
            "issn": "15491277",
            "lastpage": "0545",
            "pmid": "15971954",
            "pub_year": 2005,
            "title": "Development of a new vaccine for the prevention of Lassa fever",
            "volume": "2"
        },
        "b0110": {
            "authors": [
                {
                    "first": "Hilary G.",
                    "initial": "H.G.",
                    "last": "Morrison"
                },
                {
                    "first": "Sally P.",
                    "initial": "S.P.",
                    "last": "Bauer"
                },
                {
                    "first": "James V.",
                    "initial": "J.V.",
                    "last": "Lange"
                },
                {
                    "first": "Joseph I.",
                    "initial": "J.I.",
                    "last": "Esposito"
                },
                {
                    "first": "Joseph B.",
                    "initial": "J.B.",
                    "last": "McCormick"
                },
                {
                    "first": "David D.",
                    "initial": "D.D.",
                    "last": "Auperin"
                }
            ],
            "doi": "10.1016/0042-6822(89)90525-4",
            "firstpage": "179",
            "issn": "00426822",
            "lastpage": "188",
            "pmid": "2741340",
            "pub_year": 1989,
            "title": "Protection of guinea pigs from lassa fever by vaccinia virus recombinants expressing the nucleoprotein or the envelope glycoproteins of lassa virus",
            "volume": "171"
        },
        "b0115": {
            "authors": [
                {
                    "first": "Tom J.",
                    "initial": "T.J.",
                    "last": "Blanchard"
                },
                {
                    "first": "Antonio",
                    "initial": "A.",
                    "last": "Alcam\u00ed"
                },
                {
                    "first": "Panayiota",
                    "initial": "P.",
                    "last": "Andrea"
                },
                {
                    "first": "Geoffrey L.",
                    "initial": "G.L.",
                    "last": "Smith"
                }
            ],
            "doi": "10.1099/0022-1317-79-5-1159",
            "firstpage": "1159",
            "issn": "00221317",
            "lastpage": "1167",
            "pmid": "9603331",
            "pub_year": 1998,
            "title": "Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: Implications for use as a human vaccine",
            "volume": "79"
        },
        "b0120": {
            "authors": [
                {
                    "first": "H.",
                    "initial": "H.",
                    "last": "Meyer"
                },
                {
                    "first": "G.",
                    "initial": "G.",
                    "last": "Sutter"
                },
                {
                    "first": "A.",
                    "initial": "A.",
                    "last": "Mayr"
                }
            ],
            "doi": "10.1099/0022-1317-72-5-1031",
            "firstpage": "1031",
            "issn": "00221317",
            "lastpage": "1038",
            "pmid": "2033387",
            "pub_year": 1991,
            "title": "Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence",
            "volume": "72"
        },
        "b0125": {
            "authors": [
                {
                    "first": "Koert J.",
                    "initial": "K.J.",
                    "last": "Stittelaar"
                },
                {
                    "first": "Thijs",
                    "initial": "T.",
                    "last": "Kuiken"
                },
                {
                    "first": "Rik L.",
                    "initial": "R.L.",
                    "last": "De Swart"
                },
                {
                    "first": "Geert",
                    "initial": "G.",
                    "last": "Van Amerongen"
                },
                {
                    "first": "Helma W.",
                    "initial": "H.W.",
                    "last": "Vos"
                },
                {
                    "first": "Hubert G.M.",
                    "initial": "H.G.M.",
                    "last": "Niesters"
                },
                {
                    "first": "Pim",
                    "initial": "P.",
                    "last": "Van Schalkwijk"
                },
                {
                    "first": "Theo",
                    "initial": "T.",
                    "last": "Van Der Kwast"
                },
                {
                    "first": "Linda S.",
                    "initial": "L.S.",
                    "last": "Wyatt"
                },
                {
                    "first": "Bernard",
                    "initial": "B.",
                    "last": "Moss"
                },
                {
                    "first": "Albert D.M.E.",
                    "initial": "A.D.M.E.",
                    "last": "Osterhaus"
                }
            ],
            "doi": "10.1016/S0264-410X(01)00075-5",
            "firstpage": "3700",
            "issn": "0264410X",
            "lastpage": "3709",
            "pmid": "11395204",
            "pub_year": 2001,
            "title": "Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques",
            "volume": "19"
        },
        "b0130": {
            "authors": [
                {
                    "first": "Alfred",
                    "initial": "A.",
                    "last": "von Krempelhuber"
                },
                {
                    "first": "Jens",
                    "initial": "J.",
                    "last": "Vollmar"
                },
                {
                    "first": "Rolf",
                    "initial": "R.",
                    "last": "Pokorny"
                },
                {
                    "first": "Petra",
                    "initial": "P.",
                    "last": "Rapp"
                },
                {
                    "first": "Niels",
                    "initial": "N.",
                    "last": "Wulff"
                },
                {
                    "first": "Barbara",
                    "initial": "B.",
                    "last": "Petzold"
                },
                {
                    "first": "Amanda",
                    "initial": "A.",
                    "last": "Handley"
                },
                {
                    "first": "Lyn",
                    "initial": "L.",
                    "last": "Mateo"
                },
                {
                    "first": "Henriette",
                    "initial": "H.",
                    "last": "Siersbol"
                },
                {
                    "first": "Herwig",
                    "initial": "H.",
                    "last": "Kollaritsch"
                },
                {
                    "first": "Paul",
                    "initial": "P.",
                    "last": "Chaplin"
                }
            ],
            "doi": "10.1016/j.vaccine.2009.11.030",
            "firstpage": "1209",
            "issn": "0264410X",
            "lastpage": "1216",
            "pmid": "19944151",
            "pub_year": 2010,
            "title": "A randomized, double-blind, dose-finding Phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE\u00ae",
            "volume": "28"
        },
        "b0135": {
            "authors": [
                {
                    "first": "Joost H.C.M.",
                    "initial": "J.H.C.M.",
                    "last": "Kreijtz"
                },
                {
                    "first": "Marco",
                    "initial": "M.",
                    "last": "Goeijenbier"
                },
                {
                    "first": "Fleur M.",
                    "initial": "F.M.",
                    "last": "Moesker"
                },
                {
                    "first": "Lennert",
                    "initial": "L.",
                    "last": "van den Dries"
                },
                {
                    "first": "Simone",
                    "initial": "S.",
                    "last": "Goeijenbier"
                },
                {
                    "first": "Heidi L.M.",
                    "initial": "H.L.M.",
                    "last": "De Gruyter"
                },
                {
                    "first": "Michael H.",
                    "initial": "M.H.",
                    "last": "Lehmann"
                },
                {
                    "first": "Gerrie D.",
                    "initial": "G.D.",
                    "last": "de Mutsert"
                },
                {
                    "first": "David A.M.C.",
                    "initial": "D.A.M.C.",
                    "last": "van de Vijver"
                },
                {
                    "first": "Asisa",
                    "initial": "A.",
                    "last": "Volz"
                },
                {
                    "first": "Ron A.M.",
                    "initial": "R.A.M.",
                    "last": "Fouchier"
                },
                {
                    "first": "Eric C.M.",
                    "initial": "E.C.M.",
                    "last": "van Gorp"
                },
                {
                    "first": "Guus F.",
                    "initial": "G.F.",
                    "last": "Rimmelzwaan"
                },
                {
                    "first": "Gerd",
                    "initial": "G.",
                    "last": "Sutter"
                },
                {
                    "first": "Albert D.M.E.",
                    "initial": "A.D.M.E.",
                    "last": "Osterhaus"
                }
            ],
            "doi": "10.1016/S1473-3099(14)70963-6",
            "firstpage": "1196",
            "issn": "14733099",
            "lastpage": "1207",
            "pmid": "25455987",
            "pub_year": 2014,
            "title": "Safety and immunogenicity of a modified-vaccinia-virus-Ankara-based influenza A H5N1 vaccine: A randomised, double-blind phase 1/2a clinical trial",
            "volume": "14"
        },
        "b0140": {
            "authors": [
                {
                    "first": "A.",
                    "initial": "A.",
                    "last": "Guimar\u00e3es-Walker"
                },
                {
                    "first": "N.",
                    "initial": "N.",
                    "last": "Mackie"
                },
                {
                    "first": "S.",
                    "initial": "S.",
                    "last": "McCormack"
                },
                {
                    "first": "T.",
                    "initial": "T.",
                    "last": "Hanke"
                },
                {
                    "first": "C.",
                    "initial": "C.",
                    "last": "Schmidt"
                },
                {
                    "first": "J.",
                    "initial": "J.",
                    "last": "Gilmour"
                },
                {
                    "first": "B.",
                    "initial": "B.",
                    "last": "Barin"
                },
                {
                    "first": "A.",
                    "initial": "A.",
                    "last": "McMichael"
                },
                {
                    "first": "J.",
                    "initial": "J.",
                    "last": "Weber"
                },
                {
                    "first": "K.",
                    "initial": "K.",
                    "last": "Legg"
                },
                {
                    "first": "A.",
                    "initial": "A.",
                    "last": "Babiker"
                },
                {
                    "first": "P.",
                    "initial": "P.",
                    "last": "Hayes"
                },
                {
                    "first": "F.",
                    "initial": "F.",
                    "last": "Gotch"
                },
                {
                    "first": "C.",
                    "initial": "C.",
                    "last": "Smith"
                },
                {
                    "first": "L.",
                    "initial": "L.",
                    "last": "Dally"
                },
                {
                    "first": "L.",
                    "initial": "L.",
                    "last": "Dorrell"
                },
                {
                    "first": "I.",
                    "initial": "I.",
                    "last": "Cebere"
                },
                {
                    "first": "R.",
                    "initial": "R.",
                    "last": "Kay"
                },
                {
                    "first": "N.",
                    "initial": "N.",
                    "last": "Winstone"
                },
                {
                    "first": "S.",
                    "initial": "S.",
                    "last": "Moore"
                },
                {
                    "first": "N.",
                    "initial": "N.",
                    "last": "Goonetilleke"
                },
                {
                    "first": "P.",
                    "initial": "P.",
                    "last": "Fast"
                }
            ],
            "doi": "10.1016/j.vaccine.2008.09.016",
            "firstpage": "6671",
            "issn": "0264410X",
            "lastpage": "6677",
            "pmid": "18812202",
            "pub_year": 2008,
            "title": "Lessons from IAVI-006, a Phase I clinical trial to evaluate the safety and immunogenicity of the pTHr.HIVA DNA and MVA.HIVA vaccines in a prime-boost strategy to induce HIV-1 specific T-cell responses in healthy volunteers",
            "volume": "26"
        },
        "b0145": {
            "authors": [
                {
                    "first": "Karen R.",
                    "initial": "K.R.",
                    "last": "Buttigieg"
                },
                {
                    "first": "Stuart D.",
                    "initial": "S.D.",
                    "last": "Dowall"
                },
                {
                    "first": "Stephen",
                    "initial": "S.",
                    "last": "Findlay-Wilson"
                },
                {
                    "first": "Aleksandra",
                    "initial": "A.",
                    "last": "Miloszewska"
                },
                {
                    "first": "Emma",
                    "initial": "E.",
                    "last": "Rayner"
                },
                {
                    "first": "Roger",
                    "initial": "R.",
                    "last": "Hewson"
                },
                {
                    "first": "Miles W.",
                    "initial": "M.W.",
                    "last": "Carroll"
                }
            ],
            "doi": "10.1371/journal.pone.0091516",
            "issn": "19326203",
            "pmid": "24621656",
            "pub_year": 2014,
            "title": "A novel vaccine against Crimean-Congo haemorrhagic fever protects 100% of animals against lethal challenge in a mouse model",
            "volume": "9"
        },
        "b0150": {
            "authors": [
                {
                    "first": "David J.",
                    "initial": "D.J.",
                    "last": "Grundy"
                },
                {
                    "first": "E. T.W.",
                    "initial": "E.T.W.",
                    "last": "Bowen"
                },
                {
                    "first": "G.",
                    "initial": "G.",
                    "last": "Lloyd"
                }
            ],
            "doi": "10.1016/S0140-6736(80)90322-0",
            "firstpage": "649",
            "issn": "01406736",
            "lastpage": "650",
            "pmid": "6107442",
            "pub_year": 1980,
            "title": "ISOLATED CASE OF LASSA FEVER IN ZARIA, NORTHERN NIGERIA",
            "volume": "316"
        },
        "b0155": {
            "authors": [
                {
                    "first": "Lewis H.",
                    "initial": "L.H.",
                    "last": "McCurdy"
                },
                {
                    "first": "John A.",
                    "initial": "J.A.",
                    "last": "Rutigliano"
                },
                {
                    "first": "Teresa R.",
                    "initial": "T.R.",
                    "last": "Johnson"
                },
                {
                    "first": "Man",
                    "initial": "M.",
                    "last": "Chen"
                },
                {
                    "first": "Barney S.",
                    "initial": "B.S.",
                    "last": "Graham"
                }
            ],
            "doi": "10.1128/JVI.78.22.12471-12479.2004",
            "firstpage": "12471",
            "issn": "0022538X",
            "lastpage": "12479",
            "pmid": "15507634",
            "pub_year": 2004,
            "title": "Modified vaccinia virus Ankara immunization protects against lethal challenge with recombinant vaccinia virus expressing murine interleukin-4",
            "volume": "78"
        },
        "b0160": {
            "authors": [
                {
                    "first": "Fay",
                    "initial": "F.",
                    "last": "Wang"
                },
                {
                    "first": "John",
                    "initial": "J.",
                    "last": "Flanagan"
                },
                {
                    "first": "Nan",
                    "initial": "N.",
                    "last": "Su"
                },
                {
                    "first": "Li Chong",
                    "initial": "L.C.",
                    "last": "Wang"
                },
                {
                    "first": "Son",
                    "initial": "S.",
                    "last": "Bui"
                },
                {
                    "first": "Allissa",
                    "initial": "A.",
                    "last": "Nielson"
                },
                {
                    "first": "Xingyong",
                    "initial": "X.",
                    "last": "Wu"
                },
                {
                    "first": "Hong Thuy",
                    "initial": "H.T.",
                    "last": "Vo"
                },
                {
                    "first": "Xiao Jun",
                    "initial": "X.J.",
                    "last": "Ma"
                },
                {
                    "first": "Yuling",
                    "initial": "Y.",
                    "last": "Luo"
                }
            ],
            "doi": "10.1016/j.jmoldx.2011.08.002",
            "firstpage": "22",
            "issn": "15251578",
            "lastpage": "29",
            "pmid": "22166544",
            "pub_year": 2012,
            "title": "RNAscope: A novel in situ RNA analysis platform for formalin-fixed, paraffin-embedded tissues",
            "volume": "14"
        },
        "b0165": {
            "authors": [
                {
                    "first": "T. M.",
                    "initial": "T.M.",
                    "last": "Bell"
                },
                {
                    "first": "C. I.",
                    "initial": "C.I.",
                    "last": "Shaia"
                },
                {
                    "first": "J. J.",
                    "initial": "J.J.",
                    "last": "Bearss"
                },
                {
                    "first": "M. E.",
                    "initial": "M.E.",
                    "last": "Mattix"
                },
                {
                    "first": "K. A.",
                    "initial": "K.A.",
                    "last": "Koistinen"
                },
                {
                    "first": "S. P.",
                    "initial": "S.P.",
                    "last": "Honnold"
                },
                {
                    "first": "X.",
                    "initial": "X.",
                    "last": "Zeng"
                },
                {
                    "first": "C. D.",
                    "initial": "C.D.",
                    "last": "Blancett"
                },
                {
                    "first": "G. C.",
                    "initial": "G.C.",
                    "last": "Donnelly"
                },
                {
                    "first": "J. D.",
                    "initial": "J.D.",
                    "last": "Shamblin"
                },
                {
                    "first": "E. R.",
                    "initial": "E.R.",
                    "last": "Wilkinson"
                },
                {
                    "first": "K. A.",
                    "initial": "K.A.",
                    "last": "Cashman"
                }
            ],
            "doi": "10.1177/0300985816677153",
            "firstpage": "549",
            "issn": "03009858",
            "lastpage": "562",
            "pmid": "28438110",
            "pub_year": 2017,
            "title": "Temporal Progression of Lesions in Guinea Pigs Infected With Lassa Virus",
            "volume": "54"
        },
        "b0170": {
            "authors": [
                {
                    "first": "Tiago",
                    "initial": "T.",
                    "last": "Abreu-Mota"
                },
                {
                    "first": "Katie R.",
                    "initial": "K.R.",
                    "last": "Hagen"
                },
                {
                    "first": "Kurt",
                    "initial": "K.",
                    "last": "Cooper"
                },
                {
                    "first": "Peter B.",
                    "initial": "P.B.",
                    "last": "Jahrling"
                },
                {
                    "first": "Gene",
                    "initial": "G.",
                    "last": "Tan"
                },
                {
                    "first": "Christoph",
                    "initial": "C.",
                    "last": "Wirblich"
                },
                {
                    "first": "Reed F.",
                    "initial": "R.F.",
                    "last": "Johnson"
                },
                {
                    "first": "Matthias J.",
                    "initial": "M.J.",
                    "last": "Schnell"
                }
            ],
            "doi": "10.1038/s41467-018-06741-w",
            "issn": "20411723",
            "pmid": "30310067",
            "pub_year": 2018,
            "title": "Non-neutralizing antibodies elicited by recombinant Lassa\u2013Rabies vaccine are critical for protection against Lassa fever",
            "volume": "9"
        },
        "b0175": {
            "authors": [
                {
                    "first": "David",
                    "initial": "D.",
                    "last": "Cummins"
                },
                {
                    "first": "Joseph B.",
                    "initial": "J.B.",
                    "last": "McCormick"
                },
                {
                    "first": "Diane",
                    "initial": "D.",
                    "last": "Bennett"
                },
                {
                    "first": "James A.",
                    "initial": "J.A.",
                    "last": "Samba"
                },
                {
                    "first": "Bertha",
                    "initial": "B.",
                    "last": "Farrar"
                },
                {
                    "first": "Samuel J.",
                    "initial": "S.J.",
                    "last": "Machin"
                },
                {
                    "first": "Susan P.",
                    "initial": "S.P.",
                    "last": "Fisher-Hoch"
                }
            ],
            "doi": "10.1001/jama.1990.03450160063030",
            "firstpage": "2093",
            "issn": "00987484",
            "lastpage": "2096",
            "pmid": "2214077",
            "pub_year": 1990,
            "title": "Acute Sensorineural Deafness in Lassa Fever",
            "volume": "264"
        },
        "b0180": {
            "authors": [
                {
                    "first": "Peter O.",
                    "initial": "P.O.",
                    "last": "Okokhere"
                },
                {
                    "first": "Titus S.",
                    "initial": "T.S.",
                    "last": "Ibekwe"
                },
                {
                    "first": "George O.",
                    "initial": "G.O.",
                    "last": "Akpede"
                }
            ],
            "doi": "10.1186/1752-1947-3-36",
            "issn": "17521947",
            "pub_year": 2009,
            "title": "Sensorineural hearing loss in Lassa fever: Two case reports",
            "volume": "3"
        },
        "b0185": {
            "authors": [
                {
                    "first": "Anna",
                    "initial": "A.",
                    "last": "Grahn"
                },
                {
                    "first": "Andreas",
                    "initial": "A.",
                    "last": "Br\u00e5ve"
                },
                {
                    "first": "Martin",
                    "initial": "M.",
                    "last": "Lagging"
                },
                {
                    "first": "Leif",
                    "initial": "L.",
                    "last": "Dotevall"
                },
                {
                    "first": "David",
                    "initial": "D.",
                    "last": "Ekqvist"
                },
                {
                    "first": "Helena",
                    "initial": "H.",
                    "last": "Hammarstr\u00f6m"
                },
                {
                    "first": "Helen",
                    "initial": "H.",
                    "last": "Karlberg"
                },
                {
                    "first": "Nina",
                    "initial": "N.",
                    "last": "Lagerqvist"
                },
                {
                    "first": "Martina",
                    "initial": "M.",
                    "last": "Sansone"
                },
                {
                    "first": "Anders",
                    "initial": "A.",
                    "last": "Tegnell"
                },
                {
                    "first": "Peter",
                    "initial": "P.",
                    "last": "Ulleryd"
                },
                {
                    "first": "Marie",
                    "initial": "M.",
                    "last": "Studahl"
                }
            ],
            "doi": "10.1093/ofid/ofw198",
            "issn": "23288957",
            "pub_year": 2016,
            "title": "Imported case of lassa fever in Sweden with encephalopathy and sensorineural hearing deficit",
            "volume": "3"
        },
        "b0190": {
            "authors": [
                {
                    "first": "T. S.",
                    "initial": "T.S.",
                    "last": "Ibekwe"
                },
                {
                    "first": "P. O.",
                    "initial": "P.O.",
                    "last": "Okokhere"
                },
                {
                    "first": "D.",
                    "initial": "D.",
                    "last": "Asogun"
                },
                {
                    "first": "F. F.",
                    "initial": "F.F.",
                    "last": "Blackie"
                },
                {
                    "first": "M. M.",
                    "initial": "M.M.",
                    "last": "Nwegbu"
                },
                {
                    "first": "K. W.",
                    "initial": "K.W.",
                    "last": "Wahab"
                },
                {
                    "first": "S. A.",
                    "initial": "S.A.",
                    "last": "Omilabu"
                },
                {
                    "first": "G. O.",
                    "initial": "G.O.",
                    "last": "Akpede"
                }
            ],
            "doi": "10.1007/s00405-010-1370-4",
            "firstpage": "197",
            "issn": "09374477",
            "lastpage": "201",
            "pmid": "20809263",
            "pub_year": 2011,
            "title": "Early-onset sensorineural hearing loss in Lassa fever",
            "volume": "268"
        },
        "b0195": {
            "authors": [
                {
                    "first": "B. S.",
                    "initial": "B.S.",
                    "last": "Liao"
                },
                {
                    "first": "F. M.",
                    "initial": "F.M.",
                    "last": "Byl"
                },
                {
                    "first": "K. K.",
                    "initial": "K.K.",
                    "last": "Adour"
                }
            ],
            "doi": "10.1177/019459989210600303",
            "firstpage": "226",
            "issn": "01945998",
            "lastpage": "229",
            "pmid": "1589210",
            "pub_year": 1992,
            "title": "Audiometric comparison of Lassa fever hearing loss and idiopathic sudden hearing loss: Evidence for viral cause",
            "volume": "106"
        },
        "b0200": {
            "authors": [
                {
                    "first": "Nadezhda E.",
                    "initial": "N.E.",
                    "last": "Yun"
                },
                {
                    "first": "Shannon",
                    "initial": "S.",
                    "last": "Ronca"
                },
                {
                    "first": "Atsushi",
                    "initial": "A.",
                    "last": "Tamura"
                },
                {
                    "first": "Takaaki",
                    "initial": "T.",
                    "last": "Koma"
                },
                {
                    "first": "Alexey V.",
                    "initial": "A.V.",
                    "last": "Seregin"
                },
                {
                    "first": "Kelly T.",
                    "initial": "K.T.",
                    "last": "Dineley"
                },
                {
                    "first": "Milagros",
                    "initial": "M.",
                    "last": "Miller"
                },
                {
                    "first": "Rebecca",
                    "initial": "R.",
                    "last": "Cook"
                },
                {
                    "first": "Naoki",
                    "initial": "N.",
                    "last": "Shimizu"
                },
                {
                    "first": "Aida G.",
                    "initial": "A.G.",
                    "last": "Walker"
                },
                {
                    "first": "Jeanon N.",
                    "initial": "J.N.",
                    "last": "Smith"
                },
                {
                    "first": "Joseph N.",
                    "initial": "J.N.",
                    "last": "Fair"
                },
                {
                    "first": "Nadia",
                    "initial": "N.",
                    "last": "Wauquier"
                },
                {
                    "first": "Bayon",
                    "initial": "B.",
                    "last": "Bockarie"
                },
                {
                    "first": "Sheik Humarr",
                    "initial": "S.H.",
                    "last": "Khan"
                },
                {
                    "first": "Tomoko",
                    "initial": "T.",
                    "last": "Makishima"
                },
                {
                    "first": "Slobodan",
                    "initial": "S.",
                    "last": "Paessler"
                }
            ],
            "doi": "10.1128/JVI.02948-15",
            "firstpage": "2920",
            "issn": "0022538X",
            "lastpage": "2927",
            "pmid": "26719273",
            "pub_year": 2016,
            "title": "Animal model of sensorineural hearing loss associated with Lassa virus infection",
            "volume": "90"
        },
        "b0205": {
            "authors": [
                {
                    "first": "D. H.",
                    "initial": "D.H.",
                    "last": "Walker"
                },
                {
                    "first": "H.",
                    "initial": "H.",
                    "last": "Wulff"
                },
                {
                    "first": "J. V.",
                    "initial": "J.V.",
                    "last": "Lange"
                },
                {
                    "first": "F. A.",
                    "initial": "F.A.",
                    "last": "Murphy"
                }
            ],
            "firstpage": "523",
            "issn": "00429686",
            "lastpage": "534",
            "pmid": "821625",
            "pub_year": 1975,
            "title": "Comparative pathology of Lassa virus infection in monkeys, guinea pigs, and Mastomys natalensis",
            "volume": "52"
        },
        "b0210": null,
        "b0215": {
            "authors": [
                {
                    "first": "Tomasz A.",
                    "initial": "T.A.",
                    "last": "Leski"
                },
                {
                    "first": "Michael G.",
                    "initial": "M.G.",
                    "last": "Stockelman"
                },
                {
                    "first": "Lina M.",
                    "initial": "L.M.",
                    "last": "Moses"
                },
                {
                    "first": "Matthew",
                    "initial": "M.",
                    "last": "Park"
                },
                {
                    "first": "David A.",
                    "initial": "D.A.",
                    "last": "Stenger"
                },
                {
                    "first": "Rashid",
                    "initial": "R.",
                    "last": "Ansumana"
                },
                {
                    "first": "Daniel G.",
                    "initial": "D.G.",
                    "last": "Bausch"
                },
                {
                    "first": "Baochuan",
                    "initial": "B.",
                    "last": "Lin"
                }
            ],
            "doi": "10.3201/eid2104.141469",
            "firstpage": "609",
            "issn": "10806040",
            "lastpage": "618",
            "pmid": "25811712",
            "pub_year": 2015,
            "title": "Sequence variability and geographic distribution of Lassa Virus, Sierra Leone",
            "volume": "21"
        },
        "b0220": {
            "authors": [
                {
                    "first": "Matthew G.",
                    "initial": "M.G.",
                    "last": "Cottingham"
                },
                {
                    "first": "Miles W.",
                    "initial": "M.W.",
                    "last": "Carroll"
                }
            ],
            "doi": "10.1016/j.vaccine.2013.03.021",
            "firstpage": "4247",
            "issn": "0264410X",
            "lastpage": "4251",
            "pmid": "23523407",
            "pub_year": 2013,
            "title": "Recombinant MVA vaccines: Dispelling the myths",
            "volume": "31"
        },
        "b0225": {
            "authors": [
                {
                    "first": "Robert J.",
                    "initial": "R.J.",
                    "last": "Amato"
                },
                {
                    "first": "Robert E.",
                    "initial": "R.E.",
                    "last": "Hawkins"
                },
                {
                    "first": "Howard L.",
                    "initial": "H.L.",
                    "last": "Kaufman"
                },
                {
                    "first": "John A.",
                    "initial": "J.A.",
                    "last": "Thompson"
                },
                {
                    "first": "Piotr",
                    "initial": "P.",
                    "last": "Tomczak"
                },
                {
                    "first": "Cezary",
                    "initial": "C.",
                    "last": "Szczylik"
                },
                {
                    "first": "Mike",
                    "initial": "M.",
                    "last": "McDonald"
                },
                {
                    "first": "Sarah",
                    "initial": "S.",
                    "last": "Eastty"
                },
                {
                    "first": "William H.",
                    "initial": "W.H.",
                    "last": "Shingler"
                },
                {
                    "first": "Jackie",
                    "initial": "J.",
                    "last": "De Belin"
                },
                {
                    "first": "Madusha",
                    "initial": "M.",
                    "last": "Goonewardena"
                },
                {
                    "first": "Stuart",
                    "initial": "S.",
                    "last": "Naylor"
                },
                {
                    "first": "Richard",
                    "initial": "R.",
                    "last": "Harrop"
                }
            ],
            "doi": "10.1158/1078-0432.CCR-10-2082",
            "firstpage": "5539",
            "issn": "10780432",
            "lastpage": "5547",
            "pmid": "20881001",
            "pub_year": 2010,
            "title": "Vaccination of metastatic renal cancer patients with MVA-5T4: A randomized, double-blind, placebo-controlled phase III study",
            "volume": "16"
        }
    },
    "body_text": [
        {
            "endOffset": 30370,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0055",
            "sentence": "Recombinant Lassa NP as a crude lysate (Native Antigen Company, UK) was diluted in 0.2 M carbonate-bicarbonate buffer pH 9.4 (Thermo Scientific, UK) and used to coat Maxisorp 96-well plates (Nunc, Denmark) at 10 \u00b5g/ml in 100 \u00b5l.",
            "startOffset": 30142,
            "title": "ELISA"
        },
        {
            "endOffset": 44746,
            "parents": [],
            "secId": "s0105",
            "sentence": "The results provided from our ELISpot assays suggest 2 regions of interest to research further.",
            "startOffset": 44651,
            "title": "Discussion"
        },
        {
            "endOffset": 32141,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0060",
            "sentence": "Group 2 received a two dose vaccination of MVALassaNP in endotoxin-free PBS at 2 \u00d7 107 pfu per animal on days 0 and 14.",
            "startOffset": 32022,
            "title": "Efficacy"
        },
        {
            "endOffset": 47315,
            "parents": [],
            "secId": "s0105",
            "sentence": "One further limitation of the animal model is the route of challenge material.",
            "startOffset": 47237,
            "title": "Discussion"
        },
        {
            "endOffset": 27499,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0040",
            "sentence": "Membranes were incubated in the presence of a HRP-conjugated secondary antibody (anti-rabbit IgG peroxidase (Sigma-Aldrich) at 1/5000 in PBS-0.05%Tween) for 1 h with rocking and washed as before.",
            "startOffset": 27304,
            "title": "Detection of protein expression"
        },
        {
            "endOffset": 40708,
            "parents": [
                {
                    "id": "s0075",
                    "title": "Results"
                }
            ],
            "secId": "s0100",
            "sentence": "Although all animals were scored for lesions to some degree, the scores were higher in the tissues of non-vaccinated groups compared to the vaccinated animals (Fig. 7).",
            "startOffset": 40540,
            "title": "Histopathology"
        },
        {
            "endOffset": 18441,
            "parents": [],
            "secId": "s0005",
            "sentence": "Its genome consists of two single stranded segments of RNA termed L and an S, each encoding two open reading frames in ambisense polarity separated by a highly structured intergenic region.",
            "startOffset": 18252,
            "title": "Background"
        },
        {
            "endOffset": 28323,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0045",
            "sentence": "Group 2 received a two dose vaccination of MVALassaNP in endotoxin free PBS at 1 \u00d7 107 pfu per animal on days 0 and 14.",
            "startOffset": 28204,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 33891,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "refoffsets": {
                "b0160": {
                    "endOffset": 33826,
                    "startOffset": 33822
                }
            },
            "secId": "s0065",
            "sentence": "\u2018RNAscope\u2019 (an in-situ hybridisation method used on formalin fixed paraffin embedded tissues [32]) was used to identify LASV nucleic acid in the liver and spleen.",
            "startOffset": 33729,
            "title": "Pathological studies"
        },
        {
            "endOffset": 30943,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0055",
            "sentence": "A polyclonal anti-Lassa virus hyper immune mouse ascitic fluid sample (supplied through an agreement with BEI resources, USA) was used as a positive control sample.",
            "startOffset": 30779,
            "title": "ELISA"
        },
        {
            "endOffset": 38592,
            "parents": [
                {
                    "id": "s0075",
                    "title": "Results"
                }
            ],
            "secId": "s0095",
            "sentence": "Negative control groups consisted of animals injected with wild-type MVA or PBS buffer.",
            "startOffset": 38505,
            "title": "Efficacy"
        },
        {
            "endOffset": 42004,
            "parents": [],
            "secId": "s0105",
            "sentence": "Western blot analysis provided evidence that the nucleoprotein was expressed from an early stage of production (as early as passage 1, although the faint observed band would suggest a low concentration of MVALassaNP in the sample and this would be expected) and its expression continued throughout all subsequent passages.",
            "startOffset": 41682,
            "title": "Discussion"
        },
        {
            "endOffset": 32654,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0060",
            "sentence": "All animals were anaesthetised and challenged with 200 \u00b5l of LASV at 1 \u00d7 103 TCID50 delivered subcutaneously 24 days after the last vaccination.",
            "startOffset": 32510,
            "title": "Efficacy"
        },
        {
            "endOffset": 33296,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0060",
            "sentence": "Liver and spleen were removed for histology and viral load analysis.",
            "startOffset": 33228,
            "title": "Efficacy"
        },
        {
            "endOffset": 17664,
            "parents": [],
            "secId": "s0005",
            "sentence": "Diagnosis is often slow and as symptoms are similar to other diseases misdiagnosis is high.",
            "startOffset": 17573,
            "title": "Background"
        },
        {
            "endOffset": 25251,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0030",
            "sentence": "The plasmid DNA was transformed and amplified in bacteria (E. coli K12 DH10B\u2122 T1R) and subsequently purified.",
            "startOffset": 25142,
            "title": "Plasmid construction"
        },
        {
            "endOffset": 28686,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0045",
            "sentence": "100 \u00b5l was administered at each vaccination (50 \u00b5l into each thigh).",
            "startOffset": 28618,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 21962,
            "parents": [],
            "secId": "s0005",
            "sentence": "However, it results in high levels of expression of recombinant proteins and induces both a humoral and cell-mediated immune response.",
            "startOffset": 21828,
            "title": "Background"
        },
        {
            "endOffset": 24498,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0025",
            "sentence": "Work was performed in accordance with the Animals (Scientific Procedures) Act 1986 and the Home Office (UK) Code of Practice for the Housing and Care of Animals Used in Scientific Procedures (1989).",
            "startOffset": 24300,
            "title": "Animals"
        },
        {
            "endOffset": 17801,
            "parents": [],
            "refoffsets": {
                "b0025": {
                    "endOffset": 17800,
                    "startOffset": 17797
                }
            },
            "secId": "s0005",
            "sentence": "Disease prevention is based on controlling and limiting exposure to the host reservoir \u2013 the multimammate rat \u2013 mastomys natalensis [5].",
            "startOffset": 17665,
            "title": "Background"
        },
        {
            "endOffset": 38085,
            "parents": [
                {
                    "id": "s0075",
                    "title": "Results"
                }
            ],
            "secId": "s0090",
            "sentence": "Sera from the single dose mice recorded an average OD of \u223c 0.75 and the prime/boost an average OD of \u223c 1.2.",
            "startOffset": 37978,
            "title": "Immunogenicity \u2013 ELISA"
        },
        {
            "endOffset": 39063,
            "parents": [
                {
                    "id": "s0075",
                    "title": "Results"
                }
            ],
            "secId": "s0095",
            "sentence": "All MVALassaNP vaccinated animals were scored as healthy throughout the course of the experiment.",
            "startOffset": 38966,
            "title": "Efficacy"
        },
        {
            "endOffset": 44650,
            "parents": [],
            "secId": "s0105",
            "sentence": "To our knowledge there is not a predicted immunodominant peptide region in the NP pools that gave the strongest response, but our data may lead to identification of immunodominant peptides in the future.",
            "startOffset": 44447,
            "title": "Discussion"
        },
        {
            "endOffset": 34206,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0065",
            "sentence": "A V-LASV-GPC probe (Advanced Cell Diagnostics, USA) was incubated with the tissues for 2 h at 40 \u00b0C.",
            "startOffset": 34106,
            "title": "Pathological studies"
        },
        {
            "endOffset": 16824,
            "parents": [],
            "refoffsets": {
                "b0010": {
                    "endOffset": 16823,
                    "startOffset": 16820
                }
            },
            "secId": "s0005",
            "sentence": "During early 2018, Nigeria observed its largest outbreak to date with approximately 420 confirmed cases resulting in 106 deaths [2].",
            "startOffset": 16692,
            "title": "Background"
        },
        {
            "endOffset": 18885,
            "parents": [],
            "secId": "s0005",
            "sentence": "The NP and GP are, historically and currently, proteins of significant interest in the development of a suitable vaccine candidate for LASV.",
            "startOffset": 18745,
            "title": "Background"
        },
        {
            "endOffset": 45469,
            "parents": [],
            "secId": "s0105",
            "sentence": "If a T-cell mediated response is the cause of deafness in infected patients, clinical studies in humans will require close observations to ensure the vaccine (which enhances the T-cell response) does not also cause sensorineural hearing loss.",
            "startOffset": 45227,
            "title": "Discussion"
        },
        {
            "endOffset": 49953,
            "parents": [],
            "secId": "s0105",
            "sentence": "This research has demonstrated exciting potential for a vaccine against Lassa fever using an MVA vaccine candidate.",
            "startOffset": 49838,
            "title": "Discussion"
        },
        {
            "endOffset": 16936,
            "parents": [],
            "secId": "s0005",
            "sentence": "There are estimated to be up to 500,000 cases of Lassa fever per year with 5000 deaths attributed to the virus.",
            "startOffset": 16825,
            "title": "Background"
        },
        {
            "endOffset": 42096,
            "parents": [],
            "secId": "s0105",
            "sentence": "The purified vaccine batch observed good expression of the nucleoprotein with no breakdown.",
            "startOffset": 42005,
            "title": "Discussion"
        },
        {
            "endOffset": 45004,
            "parents": [],
            "refoffsets": {
                "b0175": {
                    "endOffset": 44891,
                    "startOffset": 44887
                },
                "b0180": {
                    "endOffset": 45003,
                    "startOffset": 44996
                },
                "b0185": {
                    "endOffset": 45003,
                    "startOffset": 44996
                },
                "b0190": {
                    "endOffset": 45003,
                    "startOffset": 44996
                }
            },
            "secId": "s0105",
            "sentence": "The association of deafness and LASV infection was first determined in 1990 [35] and since then a number of case studies have reported hearing loss in patients following LASV infection [36\u201338].",
            "startOffset": 44811,
            "title": "Discussion"
        },
        {
            "endOffset": 35256,
            "parents": [
                {
                    "id": "s0075",
                    "title": "Results"
                }
            ],
            "secId": "s0080",
            "sentence": "Infection/transfection assays produced GFP fluorescing plaques that were easy to identify and purify.",
            "startOffset": 35155,
            "title": "Vaccine constructions and production"
        },
        {
            "endOffset": 23076,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Chicken Embryo Fibroblast (CEF) cells were received from the Institute of Animal Health (Pirbright, UK) and cultured in Dulbecco\u2019s modified eagle medium (DMEM, Sigma-Aldrich) supplemented with 10% FBS, 2 mM L-glutamine, 100U penicillin and 0.1 mg/ml streptomycin (Sigma-Aldrich).",
            "startOffset": 22797,
            "title": "Cells"
        },
        {
            "endOffset": 23346,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0020",
            "sentence": "MVA strain 1974 was kindly donated by Prof B Moss (NIH, USA).",
            "startOffset": 23285,
            "title": "Viruses"
        },
        {
            "endOffset": 22797,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Baby Hamster Kidney-21 (BHK-21) cells (European Collection of Cell Cultures, UK) cultured in modified essential eagle medium (MEM) (Sigma-Aldrich) supplemented with 10% foetal bovine serum (FBS), 2 mM L-Glutamine, 100U penicillin and 0.1 mg/ml streptomycin (Sigma-Aldrich).",
            "startOffset": 22524,
            "title": "Cells"
        },
        {
            "endOffset": 25141,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0030",
            "sentence": "The cassette was inserted into an Sfil/Sfil cloning site of plasmid pMK-RQ to produce plasmid 16ADHWFP_2037865QAD_MVAlassaNP (pMVALassaNP).",
            "startOffset": 25002,
            "title": "Plasmid construction"
        },
        {
            "endOffset": 21502,
            "parents": [],
            "refoffsets": {
                "b0115": {
                    "endOffset": 21501,
                    "startOffset": 21497
                }
            },
            "secId": "s0005",
            "sentence": "As Lassa fever is endemic in an area of the world where the numbers of immunocompromised people are high, other strains of the Vaccinia virus and modified versions have been investigated to overcome the incompatibility of the vector for high risk groups [23].",
            "startOffset": 21243,
            "title": "Background"
        },
        {
            "endOffset": 31160,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0055",
            "sentence": "Plates were washed with PBS + 0.01%Tween-20 and 100 \u00b5l of a polyclonal IgG anti-mouse HRP conjugate (Sigma-Aldrich, UK) at a 1: 20,000 dilution in PBS + 0.01%Tween-20 containing 5% milk powder was added to each well.",
            "startOffset": 30944,
            "title": "ELISA"
        },
        {
            "endOffset": 37564,
            "parents": [
                {
                    "id": "s0075",
                    "title": "Results"
                }
            ],
            "secId": "s0090",
            "sentence": "Serum collected from all mice (vaccinated and un-vaccinated) was analysed for the presence of antibodies specifically to LASV nucleoprotein.",
            "startOffset": 37424,
            "title": "Immunogenicity \u2013 ELISA"
        },
        {
            "endOffset": 25001,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0030",
            "sentence": "A 24-residue linker sequence followed by a V5 epitope and stop codon was engineered downstream of NP.",
            "startOffset": 24900,
            "title": "Plasmid construction"
        },
        {
            "endOffset": 29605,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0050",
            "sentence": "Peptides spanning the Lassa NP sequence were 15 residues long, with an overlap of 10 residues between peptides.",
            "startOffset": 29494,
            "title": "ELISpot"
        },
        {
            "endOffset": 32836,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0060",
            "sentence": "All efforts were made to minimise suffering and any animal that reached a humane endpoint (body weight < 20% or < 10% with moderate clinical signs) was removed from the study early.",
            "startOffset": 32655,
            "title": "Efficacy"
        },
        {
            "endOffset": 19896,
            "parents": [],
            "refoffsets": {
                "b0075": {
                    "endOffset": 19895,
                    "startOffset": 19885
                },
                "b0085": {
                    "endOffset": 19895,
                    "startOffset": 19885
                },
                "b0090": {
                    "endOffset": 19895,
                    "startOffset": 19885
                }
            },
            "secId": "s0005",
            "sentence": "Although antibodies specific to LASV are usually produced in immunisation studies, in human disease they are more often identified at the convalescent stage of infection and not during the acute phase [15,17,18].",
            "startOffset": 19684,
            "title": "Background"
        },
        {
            "endOffset": 44224,
            "parents": [],
            "secId": "s0105",
            "sentence": "A two-dose vaccine regime offered a more enhanced T-cell response; however, encouragingly even a single vaccine was able to stimulate a significantly increased T-cell response compared to the non-vaccinated groups (P < 0.001).",
            "startOffset": 43998,
            "title": "Discussion"
        },
        {
            "endOffset": 46154,
            "parents": [],
            "refoffsets": {
                "b0070": {
                    "endOffset": 46153,
                    "startOffset": 46149
                }
            },
            "secId": "s0105",
            "sentence": "The MVALassaNP vaccine demonstrated similar protection to that described for a similar vaccine developed at Porton Down in 1987 using Vaccinia virus as the antigen delivery vehicle [14].",
            "startOffset": 45968,
            "title": "Discussion"
        },
        {
            "endOffset": 47960,
            "parents": [],
            "secId": "s0105",
            "sentence": "Although lesions were observed in splenic tissue of the vaccinated guinea pigs, they were markedly lower in numbers and less severe than those of the unvaccinated animals.",
            "startOffset": 47789,
            "title": "Discussion"
        },
        {
            "endOffset": 18632,
            "parents": [],
            "secId": "s0005",
            "sentence": "The L segment encodes the viral polymerase and zinc binding protein (Z) whilst the S segment encodes for the structural proteins \u2013 the nucleoprotein (NP) and the glycoprotein (GP) precursor.",
            "startOffset": 18442,
            "title": "Background"
        },
        {
            "endOffset": 24157,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0025",
            "sentence": "For efficacy studies, adult female guinea pigs with weights of 300\u2013350 g were supplied from Marshall BioResources.",
            "startOffset": 24043,
            "title": "Animals"
        },
        {
            "endOffset": 24299,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0025",
            "sentence": "These studies were approved by the ethical review process of PHE, Porton Down, UK and the Home Office, UK via project licence number 30/2993.",
            "startOffset": 24158,
            "title": "Animals"
        },
        {
            "endOffset": 28203,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0045",
            "sentence": "Group 1 received a single vaccine shot of MVALassaNP in endotoxin-free PBS at 1 \u00d7 107 plaque forming units (pfu) per animal on day 14.",
            "startOffset": 28069,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 33728,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0065",
            "sentence": "The severity of LASV-associated lesions in the sections of spleen and liver from each animal was assessed and scored subjectively.",
            "startOffset": 33598,
            "title": "Pathological studies"
        },
        {
            "endOffset": 38683,
            "parents": [
                {
                    "id": "s0075",
                    "title": "Results"
                }
            ],
            "secId": "s0095",
            "sentence": "At a time-point 24 days after the last vaccination, all animals were challenged with LASV.",
            "startOffset": 38593,
            "title": "Efficacy"
        },
        {
            "endOffset": 49439,
            "parents": [],
            "secId": "s0105",
            "sentence": "As variability is relatively low, LASV NP is a useful antigen candidate for vaccine production that could be efficacious across all endemic regions.",
            "startOffset": 49291,
            "title": "Discussion"
        },
        {
            "endOffset": 30134,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0050",
            "sentence": "Results are expressed as spot forming units (SFU) per 106 cells.",
            "startOffset": 30070,
            "title": "ELISpot"
        },
        {
            "endOffset": 25567,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Infected cells were transfected with pMVALassaNP using lipofectamine (Life Technologies) as directed by the manufacturer.",
            "startOffset": 25446,
            "title": "Vaccine candidate production"
        },
        {
            "endOffset": 18096,
            "parents": [],
            "refoffsets": {
                "b0015": {
                    "endOffset": 18095,
                    "startOffset": 18092
                }
            },
            "secId": "s0005",
            "sentence": "Human-to-human transmission is observed through contact with infected bodily fluids [3].",
            "startOffset": 18008,
            "title": "Background"
        },
        {
            "endOffset": 20724,
            "parents": [],
            "refoffsets": {
                "b0090": {
                    "endOffset": 20687,
                    "startOffset": 20683
                }
            },
            "secId": "s0005",
            "sentence": "Interestingly, parallel studies in non-human primates (NHPs) have shown that NP offers less protection [18] than observed in a guinea pig model.",
            "startOffset": 20580,
            "title": "Background"
        },
        {
            "endOffset": 46519,
            "parents": [],
            "secId": "s0105",
            "sentence": "It would be beneficial to follow up these studies to show that this MVALassaNP vaccine can protect against a fully lethal Lassa challenge in guinea pigs prior to human clinical studies.",
            "startOffset": 46334,
            "title": "Discussion"
        },
        {
            "endOffset": 35154,
            "parents": [
                {
                    "id": "s0075",
                    "title": "Results"
                }
            ],
            "secId": "s0080",
            "sentence": "A quality-controlled plasmid suitable for progressing into vaccine production was developed (Fig. 1).",
            "startOffset": 35053,
            "title": "Vaccine constructions and production"
        },
        {
            "endOffset": 44810,
            "parents": [],
            "secId": "s0105",
            "sentence": "One common sequalae in human\u2019s post LASV infection is deafness.",
            "startOffset": 44747,
            "title": "Discussion"
        },
        {
            "endOffset": 45785,
            "parents": [],
            "secId": "s0105",
            "sentence": "The MVALassaNP vaccine has demonstrated protection against disease progression in guinea pigs when challenged with a homologous LASV strain in a non-uniformly lethal challenge model.",
            "startOffset": 45603,
            "title": "Discussion"
        },
        {
            "endOffset": 20866,
            "parents": [],
            "refoffsets": {
                "b0090": {
                    "endOffset": 20865,
                    "startOffset": 20861
                }
            },
            "secId": "s0005",
            "sentence": "However, immunisation using GP (specifically GP1 and GP2 combined) or a GP/NP combination seem to offer the highest level of protection [18].",
            "startOffset": 20725,
            "title": "Background"
        },
        {
            "endOffset": 49177,
            "parents": [],
            "refoffsets": {
                "b0075": {
                    "endOffset": 48961,
                    "startOffset": 48957
                }
            },
            "secId": "s0105",
            "sentence": "The majority of LASV studies concentrate on the Josiah strain (from lineage IV \u2013 Sierra Leone [15]); however, this strain and the GA391 strain used in our studies are not currently circulating strains, so it may be beneficial to use circulating strains in future studies to ensure a more likely successful vaccine.",
            "startOffset": 48863,
            "title": "Discussion"
        },
        {
            "endOffset": 21744,
            "parents": [],
            "refoffsets": {
                "b0115": {
                    "endOffset": 21743,
                    "startOffset": 21736
                },
                "b0120": {
                    "endOffset": 21743,
                    "startOffset": 21736
                }
            },
            "secId": "s0005",
            "sentence": "One method was serial passage of the Vaccinia Ankara strain in Chicken Embryo Fibroblasts (CEFs) and continual passages (over 500 times) have led to the production of the highly attenuated Modified Vaccinia Ankara (MVA) virus strain [23,24].",
            "startOffset": 21503,
            "title": "Background"
        },
        {
            "endOffset": 18955,
            "parents": [],
            "secId": "s0005",
            "sentence": "There have been many attempts to develop a suitable vaccine for Lassa.",
            "startOffset": 18885,
            "title": "Background"
        },
        {
            "endOffset": 25829,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0035",
            "sentence": "MVALassaNP was amplified in CEF cells, purified by sucrose cushion centrifugation and titrated by plaque assay using CEF cells prior to in vivo use.",
            "startOffset": 25681,
            "title": "Vaccine candidate production"
        },
        {
            "endOffset": 37977,
            "parents": [
                {
                    "id": "s0075",
                    "title": "Results"
                }
            ],
            "secId": "s0090",
            "sentence": "Sera from all mice in the MVA-WT group gave ODs below the 0.09 cut off and the responses of all mice in the prime and the prime/boost vaccinated groups were greater than 0.09 (Fig. 4).",
            "startOffset": 37793,
            "title": "Immunogenicity \u2013 ELISA"
        },
        {
            "endOffset": 37625,
            "parents": [
                {
                    "id": "s0075",
                    "title": "Results"
                }
            ],
            "secId": "s0090",
            "sentence": "IgG response was measured as set out in the methods section.",
            "startOffset": 37565,
            "title": "Immunogenicity \u2013 ELISA"
        },
        {
            "endOffset": 40539,
            "parents": [
                {
                    "id": "s0075",
                    "title": "Results"
                }
            ],
            "secId": "s0100",
            "sentence": "Lesion scores were more pronounced in splenic tissue compared to liver tissue.",
            "startOffset": 40461,
            "title": "Histopathology"
        },
        {
            "endOffset": 41140,
            "parents": [],
            "secId": "s0105",
            "sentence": "This study has demonstrated that MVA is a suitable viral vector for Lassa NP encoded from Nigerian strain GA391.",
            "startOffset": 41028,
            "title": "Discussion"
        },
        {
            "endOffset": 25445,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0035",
            "sentence": "BHK-21 cells were infected with MVA 1974 at a multiplicity of infection of 0.05.",
            "startOffset": 25365,
            "title": "Vaccine candidate production"
        },
        {
            "endOffset": 29709,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0050",
            "sentence": "They were applied to cells at a final concentration of 25 \u00b5g/ml per peptide, with 20 peptides per pool.",
            "startOffset": 29606,
            "title": "ELISpot"
        },
        {
            "endOffset": 48429,
            "parents": [],
            "refoffsets": {
                "b0165": {
                    "endOffset": 48428,
                    "startOffset": 48424
                }
            },
            "secId": "s0105",
            "sentence": "The guinea pig model is a valuable in vivo model for assessment of interventions prior to advancement to NHP and human trials [33].",
            "startOffset": 48298,
            "title": "Discussion"
        },
        {
            "endOffset": 28068,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "refoffsets": {
                "b0145": {
                    "endOffset": 27995,
                    "startOffset": 27988
                },
                "b0155": {
                    "endOffset": 27995,
                    "startOffset": 27988
                }
            },
            "secId": "s0045",
            "sentence": "Vaccination studies and scheduling for prime and boost regimes were based on standard MVA protocols and previous MVA studies [29,31], 24 female 5\u20138 week old BALB/c mice were randomly divided into 4 groups.",
            "startOffset": 27863,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 19231,
            "parents": [],
            "refoffsets": {
                "b0050": {
                    "endOffset": 19150,
                    "startOffset": 19146
                },
                "b0055": {
                    "endOffset": 19169,
                    "startOffset": 19165
                },
                "b0060": {
                    "endOffset": 19200,
                    "startOffset": 19196
                },
                "b0065": {
                    "endOffset": 19230,
                    "startOffset": 19223
                },
                "b0070": {
                    "endOffset": 19230,
                    "startOffset": 19223
                }
            },
            "secId": "s0005",
            "sentence": "The different vaccine approaches include: virus-like particles [10]; DNA vaccines [11]; live-attenuated vaccines [12] and vectored vaccines [13,14].",
            "startOffset": 19083,
            "title": "Background"
        },
        {
            "endOffset": 34392,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0065",
            "sentence": "Amplification of the signal was carried out following the RNAscope protocol (RNAscope 2.5 HD Detection Reagent \u2013 Red) using the RNAscope 2.5 HD Red kit (Advanced Cell Diagnostics, USA).",
            "startOffset": 34207,
            "title": "Pathological studies"
        },
        {
            "endOffset": 29493,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0050",
            "sentence": "Cells were seeded in PVDF microtiter plates at 2 \u00d7 105 per well and re-stimulated with peptide pools (JPT, Berlin).",
            "startOffset": 29378,
            "title": "ELISpot"
        },
        {
            "endOffset": 47788,
            "parents": [],
            "secId": "s0105",
            "sentence": "Histology results provided further analysis that the vaccine protected against LASV challenge.",
            "startOffset": 47694,
            "title": "Discussion"
        },
        {
            "endOffset": 36649,
            "parents": [
                {
                    "id": "s0075",
                    "title": "Results"
                }
            ],
            "secId": "s0085",
            "sentence": "Splenocytes from the MVA-WT and PBS control mice were negative for IFN-\u03b3 production when stimulated with the Lassa NP peptides.",
            "startOffset": 36522,
            "title": "Immunogenicity \u2013 ELISpot"
        },
        {
            "endOffset": 26809,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0040",
            "sentence": "Uninfected cells were treated in the same manner as a negative control.",
            "startOffset": 26738,
            "title": "Detection of protein expression"
        },
        {
            "endOffset": 30069,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0050",
            "sentence": "Background values from wells containing cells and medium but no peptides were subtracted, and data are presented as the response to individual pools or summed across the target protein.",
            "startOffset": 29884,
            "title": "ELISpot"
        },
        {
            "endOffset": 32271,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0060",
            "sentence": "Group 3 received a two dose vaccination of MVA 1974 (wild-type) in endotoxin-free PBS at 2 \u00d7 107 pfu per animal on days 0 and 14.",
            "startOffset": 32142,
            "title": "Efficacy"
        },
        {
            "endOffset": 41259,
            "parents": [],
            "secId": "s0105",
            "sentence": "The Lassa NP gene was inserted into the MVA with ease and sequencing data suggested stability after multiple passages.",
            "startOffset": 41141,
            "title": "Discussion"
        },
        {
            "endOffset": 28453,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0045",
            "sentence": "Group 3 received a two dose vaccination of MVA 1974 (wild-type) in endotoxin-free PBS at 1 \u00d7 107 pfu per animal on days 0 and 14.",
            "startOffset": 28324,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 28851,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0045",
            "sentence": "Animals were euthanised and spleen tissue and blood were collected on day 28 after the primary vaccination.",
            "startOffset": 28744,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 35811,
            "parents": [
                {
                    "id": "s0075",
                    "title": "Results"
                }
            ],
            "secId": "s0080",
            "sentence": "A concentration of 1 \u00d7 108 pfu/ml was stored at \u221280 \u00b0C as a stock vaccine.",
            "startOffset": 35737,
            "title": "Vaccine constructions and production"
        },
        {
            "endOffset": 23581,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0020",
            "sentence": "Virus was grown and titered by TCID50 assay on VeroE6 cells (European Collection of Cell Cultures, UK).",
            "startOffset": 23478,
            "title": "Viruses"
        },
        {
            "endOffset": 45967,
            "parents": [],
            "secId": "s0105",
            "sentence": "All animals in the control groups showed clinical signs with two from the PBS group and one from the MVA-WT group removed from the study early because they reached humane endpoints.",
            "startOffset": 45786,
            "title": "Discussion"
        },
        {
            "endOffset": 48297,
            "parents": [],
            "refoffsets": {
                "b0210": {
                    "endOffset": 48296,
                    "startOffset": 48292
                }
            },
            "secId": "s0105",
            "sentence": "In previous studies, virus concentration (log10 PFU/g) was greater in the spleen compared to the liver and RNA presence in this study corroborate these findings [42].",
            "startOffset": 48131,
            "title": "Discussion"
        },
        {
            "endOffset": 26959,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0040",
            "sentence": "MVALassaNP lysates were subjected to SDS-PAGE on a 4\u201312% Bis-Tris gel (Life Technologies) and proteins were transferred to a nitrocellulose membrane.",
            "startOffset": 26810,
            "title": "Detection of protein expression"
        },
        {
            "endOffset": 48862,
            "parents": [],
            "refoffsets": {
                "b0215": {
                    "endOffset": 48861,
                    "startOffset": 48857
                }
            },
            "secId": "s0105",
            "sentence": "LASV strains are separated into distinct lineages: GA391 is from lineage III (distributed in Nigeria), lineages I and II are also distributed throughout Nigeria, and lineage IV strains are closely related and found among the other Lassa endemic countries of Western Africa [43].",
            "startOffset": 48584,
            "title": "Discussion"
        },
        {
            "endOffset": 37792,
            "parents": [
                {
                    "id": "s0075",
                    "title": "Results"
                }
            ],
            "secId": "s0090",
            "sentence": "The mean optical density (OD) obtained with the PBS mice serum plus 3 standard deviations (OD = 0.09) was used to determine a positive/negative cut off for the study.",
            "startOffset": 37626,
            "title": "Immunogenicity \u2013 ELISA"
        },
        {
            "endOffset": 16513,
            "parents": [],
            "refoffsets": {
                "b0005": {
                    "endOffset": 16512,
                    "startOffset": 16509
                }
            },
            "secId": "s0005",
            "sentence": "Lassa virus (LASV), the causative agent of Lassa fever is endemic in Western Africa, particularly in Nigeria, Sierra Leone, Guinea and Liberia [1].",
            "startOffset": 16366,
            "title": "Background"
        },
        {
            "endOffset": 27846,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0040",
            "sentence": "Molecular weights were determined using the molecular ladder MagicMark XP Western Protein Standard (Invitrogen) as a reference.",
            "startOffset": 27719,
            "title": "Detection of protein expression"
        },
        {
            "endOffset": 31764,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0055",
            "sentence": "Background absorbance values were subtracted from the sample values and results are reported as Absorbance (450 nm) at a 1:50 dilution.",
            "startOffset": 31629,
            "title": "ELISA"
        },
        {
            "endOffset": 29883,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0050",
            "sentence": "Spots were counted visually on an automated ELISpot reader (Cellular Technologies Limited, USA).",
            "startOffset": 29787,
            "title": "ELISpot"
        },
        {
            "endOffset": 34105,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0065",
            "sentence": "Tissues were pre-treated with hydrogen peroxide for 10 mins (room temperature), with target retrieval buffer for 30 mins (98\u2013101 \u00b0C) and with protease plus for 30 mins (40 \u00b0C) (all Advanced Cell Diagnostics, USA).",
            "startOffset": 33892,
            "title": "Pathological studies"
        },
        {
            "endOffset": 36521,
            "parents": [
                {
                    "id": "s0075",
                    "title": "Results"
                }
            ],
            "secId": "s0085",
            "sentence": "However, even the single vaccine regime induced a significantly increased response compared to unvaccinated mice (P < 0.0001).",
            "startOffset": 36395,
            "title": "Immunogenicity \u2013 ELISpot"
        },
        {
            "endOffset": 48583,
            "parents": [],
            "secId": "s0105",
            "sentence": "Future work is planned with a heterologous LASV challenge.",
            "startOffset": 48525,
            "title": "Discussion"
        },
        {
            "endOffset": 16691,
            "parents": [],
            "secId": "s0005",
            "sentence": "Sporadic and often large outbreaks are common with evidence of outbreaks in non-endemic neighbouring countries including; Benin, Togo, Ghana, Ivory Coast, Burkina Faso and Mali.",
            "startOffset": 16514,
            "title": "Background"
        },
        {
            "endOffset": 31497,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0055",
            "sentence": "The reaction was stopped by the addition of 100 \u00b5l of stop solution (Surmodics, USA) prepared according to the manufacturer\u2019s instructions.",
            "startOffset": 31358,
            "title": "ELISA"
        },
        {
            "endOffset": 42653,
            "parents": [],
            "refoffsets": {
                "b0145": {
                    "endOffset": 42555,
                    "startOffset": 42551
                }
            },
            "secId": "s0105",
            "sentence": "Previous use of MVA has proved its safety and suitability as a vaccine candidate [29] and the MVALassaNP vaccine in this report was well-tolerated in rodents (see supplementary data).",
            "startOffset": 42470,
            "title": "Discussion"
        },
        {
            "endOffset": 23275,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0015",
            "sentence": "VeroE6 cells (European Collection of Cell Cultures, UK) were cultured in Leibovitz\u2019s L-15 medium containing glutamax (life Technologies, UK) supplemented with 10% foetal bovine serum (Sigma-Aldrich).",
            "startOffset": 23076,
            "title": "Cells"
        },
        {
            "endOffset": 28743,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0045",
            "sentence": "Animal weights were recorded daily throughout the study.",
            "startOffset": 28687,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 38965,
            "parents": [
                {
                    "id": "s0075",
                    "title": "Results"
                }
            ],
            "secId": "s0095",
            "sentence": "Results demonstrated that all animals given MVALassaNP were protected against disease progression (Figs. 5 and 6).",
            "startOffset": 38851,
            "title": "Efficacy"
        },
        {
            "endOffset": 30618,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0055",
            "sentence": "Plates were incubated at 4 \u00b0C overnight, then washed with PBS + 0.01%Tween-20 (Sigma-Aldrich, UK) and blocked with 100 \u00b5l of 5% milk powder (Merck, Millipore, UK) in PBS + 0.01% Tween-20 at 37 \u00b0C for 1 h, before re-washing in PBS + 0.01% Tween-20.",
            "startOffset": 30371,
            "title": "ELISA"
        },
        {
            "endOffset": 35006,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0070",
            "sentence": "A two-way ANOVA (Tukey comparison) was used to compare data from different test groups in both the immunogenicity and efficacy studies.",
            "startOffset": 34871,
            "title": "Illustrations and statistics"
        },
        {
            "endOffset": 19611,
            "parents": [],
            "refoffsets": {
                "b0075": {
                    "endOffset": 19373,
                    "startOffset": 19369
                },
                "b0080": {
                    "endOffset": 19610,
                    "startOffset": 19606
                }
            },
            "secId": "s0005",
            "sentence": "For the assessment of vaccine efficacy, guinea pig and non-human primate models are the most common animals models used for LASV studies [15] There are often cost and ethical implications when choosing a suitable animal model which can limit the data availability and it is still yet to be determined whether the efficacy of animal models will truly reflect a human vaccine [16].",
            "startOffset": 19232,
            "title": "Background"
        },
        {
            "endOffset": 20109,
            "parents": [],
            "refoffsets": {
                "b0095": {
                    "endOffset": 20108,
                    "startOffset": 20104
                }
            },
            "secId": "s0005",
            "sentence": "T-cell responses are believed to be the main correlate of protection as they are detected early in infection and memory T-cells that recognise NP and GPC epitopes can be maintained for years after infection [19].",
            "startOffset": 19897,
            "title": "Background"
        },
        {
            "endOffset": 45603,
            "parents": [],
            "refoffsets": {
                "b0200": {
                    "endOffset": 45539,
                    "startOffset": 45535
                }
            },
            "secId": "s0105",
            "sentence": "Vaccination studies using a murine model developed by Yun et al. [40] could provide vaccine safety data with regards to hearing loss.",
            "startOffset": 45470,
            "title": "Discussion"
        },
        {
            "endOffset": 22120,
            "parents": [],
            "secId": "s0005",
            "sentence": "Recombinant MVA (rMVA) has been shown to be efficacious with antigens other than LASV.",
            "startOffset": 22034,
            "title": "Background"
        },
        {
            "endOffset": 22294,
            "parents": [],
            "refoffsets": {
                "b0130": {
                    "endOffset": 22170,
                    "startOffset": 22166
                },
                "b0135": {
                    "endOffset": 22269,
                    "startOffset": 22265
                },
                "b0140": {
                    "endOffset": 22279,
                    "startOffset": 22275
                },
                "b0145": {
                    "endOffset": 22293,
                    "startOffset": 22289
                }
            },
            "secId": "s0005",
            "sentence": "It was used as a successful smallpox vaccine [26] and is in different stages of development and clinical trials for viruses including influenza [27], HIV [28] and CCHF [29].",
            "startOffset": 22121,
            "title": "Background"
        },
        {
            "endOffset": 43286,
            "parents": [],
            "refoffsets": {
                "b0075": {
                    "endOffset": 43178,
                    "startOffset": 43174
                },
                "b0090": {
                    "endOffset": 43097,
                    "startOffset": 43090
                },
                "b0110": {
                    "endOffset": 43097,
                    "startOffset": 43090
                },
                "b0170": {
                    "endOffset": 43285,
                    "startOffset": 43281
                }
            },
            "secId": "s0105",
            "sentence": "The role of the humoral arm of the immune system is debatable; whilst some have shown that antibodies have little effect on reducing viral load [18,22], others suggest an important role for neutralising antibodies in protection [15] or that non-neutralising antibodies (specific to glycoprotein in this case) correlate with protection [34].",
            "startOffset": 42946,
            "title": "Discussion"
        },
        {
            "endOffset": 27303,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0040",
            "sentence": "The nitrocellulose membrane was blocked using 5% milk powder (Merck Millipore), then incubated in the presence of a primary antibody (rabbit anti-V5 polyclonal (Invitrogen) at 1/1000 in phosphate buffered saline (PBS) containing 0.05%Tween (PBS-0.05%Tween) for 1\u20132 h with rocking, before being washed 3 times in PBS-0.05%Tween (Sigma-Aldrich).",
            "startOffset": 26960,
            "title": "Detection of protein expression"
        },
        {
            "endOffset": 24648,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0025",
            "sentence": "Animals infected with LASV were housed within flexible film isolators under climate-controlled conditions in an animal containment level 4 (CL4) room.",
            "startOffset": 24498,
            "title": "Animals"
        },
        {
            "endOffset": 36788,
            "parents": [
                {
                    "id": "s0075",
                    "title": "Results"
                }
            ],
            "secId": "s0085",
            "sentence": "Splenocytes from vaccinated groups specifically displayed IFN-\u03b3 responses to two distinct regions of the nucleoprotein as shown in Fig. 3.",
            "startOffset": 36650,
            "title": "Immunogenicity \u2013 ELISpot"
        },
        {
            "endOffset": 42789,
            "parents": [],
            "secId": "s0105",
            "sentence": "The MVALassaNP vaccine has provided useful immunogenicity data suggesting that humoral and cell-mediated immune responses are triggered.",
            "startOffset": 42653,
            "title": "Discussion"
        },
        {
            "endOffset": 33227,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0060",
            "sentence": "All remaining animals were euthanised and tissues were collected on day 21 post challenge.",
            "startOffset": 33137,
            "title": "Efficacy"
        },
        {
            "endOffset": 39451,
            "parents": [
                {
                    "id": "s0075",
                    "title": "Results"
                }
            ],
            "secId": "s0095",
            "sentence": "In addition, one and two animals in the wild-type MVA and PBS groups, respectively, met humane clinical endpoints and were culled during the study.",
            "startOffset": 39304,
            "title": "Efficacy"
        },
        {
            "endOffset": 25680,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0035",
            "sentence": "The resulting recombinant MVALassaNP was serially plaque-purified 4 times in CEF cells, based on GFP expression.",
            "startOffset": 25568,
            "title": "Vaccine candidate production"
        },
        {
            "endOffset": 23407,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0020",
            "sentence": "The virus titre was determined by plaque assay in CEF cells.",
            "startOffset": 23347,
            "title": "Viruses"
        },
        {
            "endOffset": 26421,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0040",
            "sentence": "CEF cells were infected with MVALassaNP at a multiplicity of infection of 0.05 and incubated at 37 \u00b0C in MEM supplemented with 2% FBS (Sigma-Aldrich.",
            "startOffset": 26272,
            "title": "Detection of protein expression"
        },
        {
            "endOffset": 31357,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0055",
            "sentence": "Following a further 1-hour incubation at 37 \u00b0C, plates were washed with PBS + 0.01%Tween-20 and 100 \u00b5l of TMB substrate (Surmodics, USA) was added to each well and then incubated at 20 \u00b0C for 1 h.",
            "startOffset": 31161,
            "title": "ELISA"
        },
        {
            "endOffset": 43997,
            "parents": [],
            "refoffsets": {
                "b0070": {
                    "endOffset": 43839,
                    "startOffset": 43829
                },
                "b0100": {
                    "endOffset": 43839,
                    "startOffset": 43829
                },
                "b0110": {
                    "endOffset": 43839,
                    "startOffset": 43829
                }
            },
            "secId": "s0105",
            "sentence": "Induction of a cell-mediated immune response is likely to provide protective immunity to LASV [14,20,22] and this study demonstrated a significantly heightened IFN-\u03b3 stimulation in all MVALassaNP vaccinated animals compared to non-vaccinated animals (P < 0.001).",
            "startOffset": 43735,
            "title": "Discussion"
        },
        {
            "endOffset": 17236,
            "parents": [],
            "refoffsets": {
                "b0020": {
                    "endOffset": 17235,
                    "startOffset": 17232
                }
            },
            "secId": "s0005",
            "sentence": "The disease is especially severe in late pregnancy with maternal death and or foetal loss in up to 90% of cases in the third trimester [4].",
            "startOffset": 17097,
            "title": "Background"
        },
        {
            "endOffset": 35579,
            "parents": [
                {
                    "id": "s0075",
                    "title": "Results"
                }
            ],
            "secId": "s0080",
            "sentence": "Pick P4(5.5.3.2) was chosen to take forward as determined by sequencing data.",
            "startOffset": 35502,
            "title": "Vaccine constructions and production"
        },
        {
            "endOffset": 37061,
            "parents": [
                {
                    "id": "s0075",
                    "title": "Results"
                }
            ],
            "secId": "s0085",
            "sentence": "A two-way ANOVA revealed significant differences between the prime and prime/boost vaccinated groups of mice in pool 2 (P < 0.0001) and 4 (P < 0.0001) suggesting that a prime/boost vaccination regime elicits a stronger immune response compared to a prime vaccination only.",
            "startOffset": 36789,
            "title": "Immunogenicity \u2013 ELISpot"
        },
        {
            "endOffset": 18007,
            "parents": [],
            "refoffsets": {
                "b0030": {
                    "endOffset": 18006,
                    "startOffset": 18003
                }
            },
            "secId": "s0005",
            "sentence": "Transmission of infection is predominantly through contact with the urine/faeces of the host rodent, although consumption of rodent meat is commonplace in many regions increasing the risk of infection [6].",
            "startOffset": 17802,
            "title": "Background"
        },
        {
            "endOffset": 49575,
            "parents": [],
            "secId": "s0105",
            "sentence": "MVA is a useful vaccine vector for use with LASV antigens as it demonstrates many favourable qualities for use in Lassa endemic regions.",
            "startOffset": 49439,
            "title": "Discussion"
        },
        {
            "endOffset": 26238,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Genomic DNA from infected cells was extracted using the Wizard SV genomic DNA purification system (Promega, USA) and used as a template in PCR with KAPA2G Fast HotStart PCR Kit (KAPA Biosystems, USA) for genotype analysis.",
            "startOffset": 26016,
            "title": "Vaccine candidate production"
        },
        {
            "endOffset": 35736,
            "parents": [
                {
                    "id": "s0075",
                    "title": "Results"
                }
            ],
            "secId": "s0080",
            "sentence": "Western blot analysis confirmed the expression of protein with the V5 tag (Fig. 2b) and, following amplification and purification, the vaccine was titrated.",
            "startOffset": 35580,
            "title": "Vaccine constructions and production"
        },
        {
            "endOffset": 27718,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0040",
            "sentence": "Protein expression was determined by detection of bound antibody using a Pierce ECL WB substrate kit (Thermo Fisher) according to the manufacturer\u2019s instructions and visualised in a Chemi-Lluminescent Imager (Syngene).",
            "startOffset": 27500,
            "title": "Detection of protein expression"
        },
        {
            "endOffset": 38850,
            "parents": [
                {
                    "id": "s0075",
                    "title": "Results"
                }
            ],
            "secId": "s0095",
            "sentence": "Guinea pigs were weighed and had their temperatures recorded daily; assessments of clinical symptoms and scoring were performed by experienced veterinary technicians.",
            "startOffset": 38684,
            "title": "Efficacy"
        },
        {
            "endOffset": 33494,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0065",
            "sentence": "Liver and spleen samples were collected and fixed by immersion in 10% neutral buffered formalin (NBF) for at least 21 days before being routinely processed into paraffin wax.",
            "startOffset": 33320,
            "title": "Pathological studies"
        },
        {
            "endOffset": 17395,
            "parents": [],
            "refoffsets": {
                "b0010": {
                    "endOffset": 17394,
                    "startOffset": 17391
                }
            },
            "secId": "s0005",
            "sentence": "The majority of mild cases recover fully; however, deafness occurs in approximately 25% of positive cases with only half of these cases regaining hearing [2].",
            "startOffset": 17237,
            "title": "Background"
        },
        {
            "endOffset": 23477,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "refoffsets": {
                "b0150": {
                    "endOffset": 23476,
                    "startOffset": 23472
                }
            },
            "secId": "s0020",
            "sentence": "LASV (strain GA391) was isolated from a case in Northern Nigeria [30].",
            "startOffset": 23407,
            "title": "Viruses"
        },
        {
            "endOffset": 39830,
            "parents": [
                {
                    "id": "s0075",
                    "title": "Results"
                }
            ],
            "secId": "s0100",
            "sentence": "Splenic lesions attributed to LASV infection comprised: (a) heterophilic splenitis (an increased number of heterophils in the splenic red pulp); (b) depletion of lymphocytes from the splenic follicles (white pulp); (c) peri-follicular monocytosis and a diffuse increase in the pale-staining monocytes in the red pulp; and (d) diffuse monocytosis of the red pulp.",
            "startOffset": 39468,
            "title": "Histopathology"
        },
        {
            "endOffset": 22034,
            "parents": [],
            "refoffsets": {
                "b0115": {
                    "endOffset": 22033,
                    "startOffset": 22026
                },
                "b0125": {
                    "endOffset": 22033,
                    "startOffset": 22026
                }
            },
            "secId": "s0005",
            "sentence": "These characteristics make it a useful vaccine vector platform [23,25].",
            "startOffset": 21963,
            "title": "Background"
        },
        {
            "endOffset": 46867,
            "parents": [],
            "secId": "s0105",
            "sentence": "The NHP model may align better with human infection and as such provide more telling results prior to vaccination in humans.",
            "startOffset": 46743,
            "title": "Discussion"
        },
        {
            "endOffset": 29377,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0050",
            "sentence": "Splenocytes were assessed for their antigen recall response via IFN-\u03b3 ELISpot (Mabtech, Sweden), performed as per the manufacturer\u2019s instructions.",
            "startOffset": 29231,
            "title": "ELISpot"
        },
        {
            "endOffset": 42175,
            "parents": [],
            "secId": "s0105",
            "sentence": "The Western blot used antibody detection of the V5 tag added to the construct.",
            "startOffset": 42097,
            "title": "Discussion"
        },
        {
            "endOffset": 26737,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0040",
            "sentence": "Cells were lysed with 1x LDS Nupage\u00ae reducing sample buffer (Nupage\u00ae LDS sample buffer containing 1x Nupage\u00ae sample reducing buffer) (Thermo Fisher, UK), transferred to Eppendorf tubes and heated at 70 \u00b0C for 10 min.",
            "startOffset": 26521,
            "title": "Detection of protein expression"
        },
        {
            "endOffset": 37399,
            "parents": [
                {
                    "id": "s0075",
                    "title": "Results"
                }
            ],
            "secId": "s0085",
            "sentence": "There were small (non-significant) responses detected to pools 1, 3, 5, 6 and 7 (particularly groups 1, 6 and 7) for the prime/boost and prime groups compared to unvaccinated groups.",
            "startOffset": 37217,
            "title": "Immunogenicity \u2013 ELISpot"
        },
        {
            "endOffset": 36014,
            "parents": [
                {
                    "id": "s0075",
                    "title": "Results"
                }
            ],
            "secId": "s0085",
            "sentence": "All mice gained weight and no clinical signs were observed (Supplementary data Fig. 1).",
            "startOffset": 35927,
            "title": "Immunogenicity \u2013 ELISpot"
        },
        {
            "endOffset": 40263,
            "parents": [
                {
                    "id": "s0075",
                    "title": "Results"
                }
            ],
            "secId": "s0100",
            "sentence": "Liver lesions attributed to Lassa virus comprised: (a) individual hepatocyte cell death, frequently accompanied by small numbers of mononuclear (lymphocytes, macrophages and plasma cells) inflammatory cells; (b) foci of mononuclear inflammatory cells within hepatic sinusoids (sinusoidal inflammation); (c) infiltration of portal triads by mononuclear inflammatory cells; and (d) the presence of crisp edged vacuoles in hepatocytes.",
            "startOffset": 39831,
            "title": "Histopathology"
        },
        {
            "endOffset": 20991,
            "parents": [],
            "secId": "s0005",
            "sentence": "Despite promising data, there has been limited progression into pre-clinical trials and there is still no vaccine available.",
            "startOffset": 20867,
            "title": "Background"
        },
        {
            "endOffset": 32021,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0060",
            "sentence": "Group 1 received a single vaccination with MVALassaNP in endotoxin-free PBS at 2 \u00d7 107 pfu per animal on day 14.",
            "startOffset": 31909,
            "title": "Efficacy"
        },
        {
            "endOffset": 33597,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0065",
            "sentence": "Sections of 4 \u00b5m were cut, stained with haematoxylin and eosin (H&E) and examined by light microscopy.",
            "startOffset": 33495,
            "title": "Pathological studies"
        },
        {
            "endOffset": 18744,
            "parents": [],
            "refoffsets": {
                "b0040": {
                    "endOffset": 18743,
                    "startOffset": 18740
                }
            },
            "secId": "s0005",
            "sentence": "The glycoprotein is cleaved post translation to glycoproteins GP1 and GP2, and SSP (stable signal protein) [8].",
            "startOffset": 18633,
            "title": "Background"
        },
        {
            "endOffset": 36394,
            "parents": [
                {
                    "id": "s0075",
                    "title": "Results"
                }
            ],
            "secId": "s0085",
            "sentence": "Stimulation of IFN-\u03b3 production in splenocytes by Lassa NP peptide pools was significantly increased in cells from mice vaccinated with a prime/boost regimen (P < 0.0001).",
            "startOffset": 36223,
            "title": "Immunogenicity \u2013 ELISpot"
        },
        {
            "endOffset": 37216,
            "parents": [
                {
                    "id": "s0075",
                    "title": "Results"
                }
            ],
            "secId": "s0085",
            "sentence": "However, even a single dose of MVALassaNP induced a significantly increased response (P < 0.0001) compared to the control groups of wild type-MVA and PBS.",
            "startOffset": 37062,
            "title": "Immunogenicity \u2013 ELISpot"
        },
        {
            "endOffset": 41017,
            "parents": [
                {
                    "id": "s0075",
                    "title": "Results"
                }
            ],
            "secId": "s0100",
            "sentence": "In comparison, LASV RNA was detected in all non-vaccinated animals.",
            "startOffset": 40950,
            "title": "Histopathology"
        },
        {
            "endOffset": 46742,
            "parents": [],
            "refoffsets": {
                "b0070": {
                    "endOffset": 46741,
                    "startOffset": 46734
                },
                "b0090": {
                    "endOffset": 46741,
                    "startOffset": 46734
                }
            },
            "secId": "s0105",
            "sentence": "It would also be beneficial to determine immunogenicity and efficacy of this vaccine in an NHP model as it has been previously shown that protection and cell-mediated responses differ between guinea pigs and NHP\u2019s [14,18].",
            "startOffset": 46520,
            "title": "Discussion"
        },
        {
            "endOffset": 28617,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0045",
            "sentence": "All mice were injected intramuscularly into the caudal thigh.",
            "startOffset": 28556,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 31628,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0055",
            "sentence": "Plates were read at 450 nm using an absorbance reader and analysed with Softmax Pro version 5.2 software (Molecular Devices, USA).",
            "startOffset": 31498,
            "title": "ELISA"
        },
        {
            "endOffset": 31823,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0055",
            "sentence": "Data was illustrated and analysed using Graph Pad Prism 7.",
            "startOffset": 31765,
            "title": "ELISA"
        },
        {
            "endOffset": 44446,
            "parents": [],
            "refoffsets": {
                "b0090": {
                    "endOffset": 44445,
                    "startOffset": 44441
                }
            },
            "secId": "s0105",
            "sentence": "This suggests that the LASV NP alone can trigger the necessary immune responses to LASV infection and could act as a standalone vaccine without the need for the LASV glycoprotein, as others have previously suggested [18].",
            "startOffset": 44225,
            "title": "Discussion"
        },
        {
            "endOffset": 46333,
            "parents": [],
            "secId": "s0105",
            "sentence": "Our data is the first to demonstrate that an MVA vaccine containing Lassa NP is sufficient to protect at least against progression of disease in a challenge model in guinea pigs.",
            "startOffset": 46155,
            "title": "Discussion"
        },
        {
            "endOffset": 38504,
            "parents": [
                {
                    "id": "s0075",
                    "title": "Results"
                }
            ],
            "secId": "s0095",
            "sentence": "Guinea pigs were vaccinated with a single dose of MVALassaNP or two doses in a prime-boost regime, spaced two weeks apart.",
            "startOffset": 38382,
            "title": "Efficacy"
        },
        {
            "endOffset": 35501,
            "parents": [
                {
                    "id": "s0075",
                    "title": "Results"
                }
            ],
            "secId": "s0080",
            "sentence": "Next Generation Sequencing (NGS) using an Illumina Hiseq method showed passaged picks to be congruent with the initial reference sequence.",
            "startOffset": 35363,
            "title": "Vaccine constructions and production"
        },
        {
            "endOffset": 19683,
            "parents": [],
            "secId": "s0005",
            "sentence": "The correlate of protection is still poorly understood for Lassa fever.",
            "startOffset": 19612,
            "title": "Background"
        },
        {
            "endOffset": 28903,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0045",
            "sentence": "All efforts were made to minimise animal suffering.",
            "startOffset": 28852,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 33137,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "refoffsets": {
                "b0145": {
                    "endOffset": 33005,
                    "startOffset": 33001
                }
            },
            "secId": "s0060",
            "sentence": "Clinical observations other than weight and temperature were assigned a numerical value depending on their severity to allow the data to be graphically illustrated [29]; normal/no observations = 0; ruffled fur = 2; lethargy = 3; hunched = 3; laboured breathing = 5; culled as met humane endpoint = 5.",
            "startOffset": 32837,
            "title": "Efficacy"
        },
        {
            "endOffset": 38371,
            "parents": [
                {
                    "id": "s0075",
                    "title": "Results"
                }
            ],
            "secId": "s0090",
            "sentence": "The difference between the response in the prime/boost group and that in the single dose group was significant (<0.0001 using a one-way ANOVA with multiple comparisons); however, the single dose also gave a significantly increased response compared to both control groups (P < 0.0001).",
            "startOffset": 38086,
            "title": "Immunogenicity \u2013 ELISA"
        },
        {
            "endOffset": 47236,
            "parents": [],
            "secId": "s0105",
            "sentence": "Use of a lethal dose of challenge virus would allow protection to be ascertained; however, as the mortality rate for Lassa fever does not reach 100%, the model system we used here is representative of natural disease severity.",
            "startOffset": 47010,
            "title": "Discussion"
        },
        {
            "endOffset": 50167,
            "parents": [],
            "secId": "s0105",
            "sentence": "Our vaccine has demonstrated strong immunogenicity and protection against disease progression in a small animal model, thus suggesting that it has the potential for advancement to pre-clinical and clinical trials.",
            "startOffset": 49954,
            "title": "Discussion"
        },
        {
            "endOffset": 35926,
            "parents": [
                {
                    "id": "s0075",
                    "title": "Results"
                }
            ],
            "secId": "s0085",
            "sentence": "The vaccine candidate was observed to be well tolerated during the immunogenicity study.",
            "startOffset": 35838,
            "title": "Immunogenicity \u2013 ELISpot"
        },
        {
            "endOffset": 49290,
            "parents": [],
            "refoffsets": {
                "b0040": {
                    "endOffset": 49289,
                    "startOffset": 49286
                }
            },
            "secId": "s0105",
            "sentence": "LASV NP has been shown to have some variability (12% at the amino acid level) across the different lineages [8].",
            "startOffset": 49178,
            "title": "Discussion"
        },
        {
            "endOffset": 29230,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0050",
            "sentence": "Splenocytes were resuspended in RPMI medium (Sigma-Aldrich) supplemented with 5% FBS, 2 mM L-Glutamine, 100U penicillin & 0.1 mg/ml streptomycin, 50 mM 2-mercaptoethanol and 25 mM HEPES solution (Sigma-Aldrich).",
            "startOffset": 29019,
            "title": "ELISpot"
        },
        {
            "endOffset": 49707,
            "parents": [],
            "refoffsets": {
                "b0115": {
                    "endOffset": 49706,
                    "startOffset": 49699
                },
                "b0220": {
                    "endOffset": 49706,
                    "startOffset": 49699
                }
            },
            "secId": "s0105",
            "sentence": "Its limited replication in mammalian cells and high capacity to accommodate foreign genes make it a good vaccine candidate [23,44].",
            "startOffset": 49576,
            "title": "Discussion"
        },
        {
            "endOffset": 32373,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0060",
            "sentence": "Group 4 received a two dose vaccination of endotoxin-free PBS as a negative control on days 0 and 14.",
            "startOffset": 32272,
            "title": "Efficacy"
        },
        {
            "endOffset": 26015,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Plaques were visualised using GFP fluorescence and by immunostaining with rabbit anti-vaccinia antibody (AbD Serotec, UK) and Vectastain Universal ABC-AP kit (Vector laboratories, USA).",
            "startOffset": 25830,
            "title": "Vaccine candidate production"
        },
        {
            "endOffset": 40367,
            "parents": [
                {
                    "id": "s0075",
                    "title": "Results"
                }
            ],
            "refoffsets": {
                "b0165": {
                    "endOffset": 40366,
                    "startOffset": 40362
                }
            },
            "secId": "s0100",
            "sentence": "Bell et al. have previously described vacuolation resulting from intracellular lipid accumulation [33].",
            "startOffset": 40264,
            "title": "Histopathology"
        },
        {
            "endOffset": 47694,
            "parents": [],
            "secId": "s0105",
            "sentence": "Due to safety implications of handling a high consequence pathogen, working with animal models in a high containment laboratory, and ensuring conformity of challenge in all animals, LASV was administered subcutaneously, whilst this route does not mimic most natural human infections, it is representative of animal bite and potential exposure through hospital/medical incidents.",
            "startOffset": 47316,
            "title": "Discussion"
        },
        {
            "endOffset": 34726,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0065",
            "sentence": "Slides with an occasional single positive cell scored 1, slides with scattered positive cells scored 2, slides with frequent positive cells scored 3, slides with marked patchy to diffuse presence of positive cells scored 4.",
            "startOffset": 34503,
            "title": "Pathological studies"
        },
        {
            "endOffset": 42470,
            "parents": [],
            "secId": "s0105",
            "sentence": "In clinical studies the vaccine will undergo alterations; GFP and V5 markers will be removed prior to human studies to ensure only essential proteins are included; therefore, it would be preferable in subsequent assays to detect the LASV NP itself and this should be explored in future studies.",
            "startOffset": 42176,
            "title": "Discussion"
        },
        {
            "endOffset": 24042,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0025",
            "sentence": "For immunogenicity studies, 24 adult female BALB/c aged 5\u20138 weeks were supplied from Charles River.",
            "startOffset": 23943,
            "title": "Animals"
        },
        {
            "endOffset": 31908,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0060",
            "sentence": "40 female Dunkin-Hartley guinea pigs were randomly divided into 4 groups.",
            "startOffset": 31835,
            "title": "Efficacy"
        },
        {
            "endOffset": 40774,
            "parents": [
                {
                    "id": "s0075",
                    "title": "Results"
                }
            ],
            "secId": "s0100",
            "sentence": "Tables 1 and 2 document all lesions and severity for all animals.",
            "startOffset": 40709,
            "title": "Histopathology"
        },
        {
            "endOffset": 17572,
            "parents": [],
            "secId": "s0005",
            "sentence": "There is currently no vaccine for Lassa fever \u2013 the antiviral Ribavirin is the only treatment for LASV infection, but it is only effective when administered in early infection.",
            "startOffset": 17396,
            "title": "Background"
        },
        {
            "endOffset": 35362,
            "parents": [
                {
                    "id": "s0075",
                    "title": "Results"
                }
            ],
            "secId": "s0080",
            "sentence": "PCR confirmed the presence of rMVALassaNP with no evidence of wild-type MVA after purification (Fig. 2a).",
            "startOffset": 35257,
            "title": "Vaccine constructions and production"
        },
        {
            "endOffset": 49838,
            "parents": [],
            "refoffsets": {
                "b0220": {
                    "endOffset": 49837,
                    "startOffset": 49830
                },
                "b0225": {
                    "endOffset": 49837,
                    "startOffset": 49830
                }
            },
            "secId": "s0105",
            "sentence": "It does not require a cold chain so can be used in low income countries, and it is capable of large scale GMP manufacture [44,45].",
            "startOffset": 49708,
            "title": "Discussion"
        },
        {
            "endOffset": 26520,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0040",
            "sentence": "The medium was removed after 48 h once GFP fluorescence and CPE was observed microscopically.",
            "startOffset": 26427,
            "title": "Detection of protein expression"
        },
        {
            "endOffset": 47009,
            "parents": [],
            "secId": "s0105",
            "sentence": "This study used a non-lethal LASV challenge and clinical parameters (weight, temperature and clinical scores) were the readout of protection.",
            "startOffset": 46868,
            "title": "Discussion"
        },
        {
            "endOffset": 20232,
            "parents": [],
            "refoffsets": {
                "b0070": {
                    "endOffset": 20231,
                    "startOffset": 20221
                },
                "b0100": {
                    "endOffset": 20231,
                    "startOffset": 20221
                },
                "b0105": {
                    "endOffset": 20231,
                    "startOffset": 20221
                }
            },
            "secId": "s0005",
            "sentence": "Previous attempts to use Vaccinia virus (VV) as a viral vaccine vector for LASV proteins have described success [14,20,21].",
            "startOffset": 20109,
            "title": "Background"
        },
        {
            "endOffset": 45226,
            "parents": [],
            "refoffsets": {
                "b0175": {
                    "endOffset": 45150,
                    "startOffset": 45146
                },
                "b0195": {
                    "endOffset": 45178,
                    "startOffset": 45174
                }
            },
            "secId": "s0105",
            "sentence": "The cause of hearing loss is still not fully determined; most studies suggest it to be either attributed to the individual\u2019s immune response [35], although viral damage [39], or a combination of the two are also reported.",
            "startOffset": 45005,
            "title": "Discussion"
        },
        {
            "endOffset": 29018,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0050",
            "sentence": "Spleens from test animals were collected aseptically and homogenised, and the red blood cells were lysed.",
            "startOffset": 28913,
            "title": "ELISpot"
        },
        {
            "endOffset": 19082,
            "parents": [],
            "refoffsets": {
                "b0045": {
                    "endOffset": 19081,
                    "startOffset": 19078
                }
            },
            "secId": "s0005",
            "sentence": "According to the WHO there are over 14 Lassa vaccine candidates in the pipeline, but only one has reached clinical trials [9].",
            "startOffset": 18956,
            "title": "Background"
        },
        {
            "endOffset": 26426,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0040",
            "sentence": "UK).",
            "startOffset": 26422,
            "title": "Detection of protein expression"
        },
        {
            "endOffset": 39303,
            "parents": [
                {
                    "id": "s0075",
                    "title": "Results"
                }
            ],
            "secId": "s0095",
            "sentence": "In contrast, animals given wild-type MVA or PBS buffer all exhibited weight loss, temperature rises and showed clear clinical signs of disease including laboured breathing, hunched prostration and general lethargy after challenge (Fig. 5).",
            "startOffset": 39064,
            "title": "Efficacy"
        },
        {
            "endOffset": 40949,
            "parents": [
                {
                    "id": "s0075",
                    "title": "Results"
                }
            ],
            "secId": "s0100",
            "sentence": "RNAscope analysis demonstrated that the vaccinated groups had less LASV RNA present in both the liver and spleen, with a number of animals displaying no presence of LASV RNA.",
            "startOffset": 40775,
            "title": "Histopathology"
        },
        {
            "endOffset": 34502,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0065",
            "sentence": "The presence of cells showing LASV RNA was assessed subjectively by a board-certified veterinary pathologist.",
            "startOffset": 34393,
            "title": "Pathological studies"
        },
        {
            "endOffset": 22494,
            "parents": [],
            "secId": "s0005",
            "sentence": "This study initiated the pre-clinical development of a Lassa fever vaccine candidate using rMVA as a vector and assessed the immunogenicity and the efficacy of the vaccine candidate in a rodent model.",
            "startOffset": 22294,
            "title": "Background"
        },
        {
            "endOffset": 23814,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0020",
            "sentence": "LASV for the guinea pig challenge studies was passaged twice to ensure the virus was capable of causing disease and to increase disease severity, with virus from spleen homogenates being used for passaging the virus into new animals.",
            "startOffset": 23581,
            "title": "Viruses"
        },
        {
            "endOffset": 32509,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0060",
            "sentence": "All animals were injected intramuscularly into the caudal thigh \u2212 200 \u00b5l was administered at each vaccination (100 \u00b5l into each thigh).",
            "startOffset": 32374,
            "title": "Efficacy"
        },
        {
            "endOffset": 43587,
            "parents": [],
            "secId": "s0105",
            "sentence": "Nevertheless, we have demonstrated that MVALassaNP is able to induce an IgG response which may be linked to protection \u2013 however further data is required to determine the significance of the antibody response and to determine whether protection is conferred from the humoral arm of the immune system.",
            "startOffset": 43287,
            "title": "Discussion"
        },
        {
            "endOffset": 43735,
            "parents": [],
            "secId": "s0105",
            "sentence": "Due to the NP antigen being an internal viral antigen the mechanism of the antibody may be through antibody dependant cellular cytotoxicity (ADCC).",
            "startOffset": 43588,
            "title": "Discussion"
        },
        {
            "endOffset": 28555,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0045",
            "sentence": "Group 4 received a two dose vaccination of endotoxin-free PBS as a negative control on days 0 and 14.",
            "startOffset": 28454,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 20579,
            "parents": [],
            "refoffsets": {
                "b0110": {
                    "endOffset": 20578,
                    "startOffset": 20574
                }
            },
            "secId": "s0005",
            "sentence": "LASV NP and GP derived from the Josiah strain of LASV inserted into VV (New York Board of Health strain) have demonstrated similar observations [22].",
            "startOffset": 20430,
            "title": "Background"
        },
        {
            "endOffset": 21242,
            "parents": [],
            "secId": "s0005",
            "sentence": "The use of Vaccinia as a vector is not novel, it was successfully used in the eradication campaign of smallpox virus, but safety complications arising particularly in immunocompromised individuals halted its use as a suitable vaccine vector candidate.",
            "startOffset": 20991,
            "title": "Background"
        },
        {
            "endOffset": 21827,
            "parents": [],
            "secId": "s0005",
            "sentence": "MVA does not fully replicate in mammalian cells and is avirulent in animal models.",
            "startOffset": 21745,
            "title": "Background"
        },
        {
            "endOffset": 41388,
            "parents": [],
            "secId": "s0105",
            "sentence": "PCR confirmation of the MVALassaNP showed bands of the expected size of 3.1 kb compared to the expected size of MVA\u2013WT (0.5 kb).",
            "startOffset": 41260,
            "title": "Discussion"
        },
        {
            "endOffset": 48130,
            "parents": [],
            "refoffsets": {
                "b0165": {
                    "endOffset": 48049,
                    "startOffset": 48042
                },
                "b0205": {
                    "endOffset": 48049,
                    "startOffset": 48042
                }
            },
            "secId": "s0105",
            "sentence": "The observations in guinea pig livers were similar to those described previously [33,41] with lesions that were less severe although still present in vaccinated animals.",
            "startOffset": 47961,
            "title": "Discussion"
        },
        {
            "endOffset": 34870,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0070",
            "sentence": "All data illustrations and statistical analysis was performed using GraphPad Prism 7.0 software (GraphPad, USA).",
            "startOffset": 34758,
            "title": "Illustrations and statistics"
        },
        {
            "endOffset": 40460,
            "parents": [
                {
                    "id": "s0075",
                    "title": "Results"
                }
            ],
            "secId": "s0100",
            "sentence": "All the lesions were scored as 0 = none; 1 = minimal; 2 = mild; 3 = moderate and 4 = marked.",
            "startOffset": 40368,
            "title": "Histopathology"
        },
        {
            "endOffset": 18251,
            "parents": [],
            "refoffsets": {
                "b0035": {
                    "endOffset": 18250,
                    "startOffset": 18247
                }
            },
            "secId": "s0005",
            "sentence": "LASV belongs to the Old World (OW) group (former lymphocytic choriomeningitis virus, LCMV-LASV sero-complex), genus Mammarenavirus family Arenaviridae [7].",
            "startOffset": 18096,
            "title": "Background"
        },
        {
            "endOffset": 25334,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Its concentration was determined by GeneArt (Thermo Fisher) using UV spectroscopy.",
            "startOffset": 25252,
            "title": "Plasmid construction"
        },
        {
            "endOffset": 36222,
            "parents": [
                {
                    "id": "s0075",
                    "title": "Results"
                }
            ],
            "secId": "s0085",
            "sentence": "The ELISpot method was performed to measure IFN-\u03b3 secreting cells in response to a Lassa nucleoprotein stimulus and to determine if the response is enhanced in vaccinated animals compared to control animals.",
            "startOffset": 36015,
            "title": "Immunogenicity \u2013 ELISpot"
        },
        {
            "endOffset": 41681,
            "parents": [],
            "secId": "s0105",
            "sentence": "Next Generation Sequencing (NGS) using an Illumina Hiseq also provided evidence that no wild type MVA was present in the final vaccine batch and there were no Single Nucleotide Polymorphisms (SNPs) or other mutations suggesting that a pure recombinant vaccine is easy to produce and maintain.",
            "startOffset": 41389,
            "title": "Discussion"
        },
        {
            "endOffset": 20429,
            "parents": [],
            "refoffsets": {
                "b0070": {
                    "endOffset": 20428,
                    "startOffset": 20424
                }
            },
            "secId": "s0005",
            "sentence": "Full protection against a lethal challenge model (using LASV strain GA391) was observed in guinea pigs immunised with LASV nucleoprotein derived from GA391 inserted into the VV Lister strain [14].",
            "startOffset": 20233,
            "title": "Background"
        },
        {
            "endOffset": 30778,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0055",
            "sentence": "Samples were diluted 1:50 in 5% milk powder in PBS + 0.01% Tween-20 buffer, added to the plates in triplicate (100 \u00b5l per well) and incubated at 37 \u00b0C for 1 h.",
            "startOffset": 30619,
            "title": "ELISA"
        },
        {
            "endOffset": 17096,
            "parents": [],
            "refoffsets": {
                "b0015": {
                    "endOffset": 17095,
                    "startOffset": 17092
                }
            },
            "secId": "s0005",
            "sentence": "The overall mortality rate is relatively low as many infections are mild or even asymptomatic, but during outbreaks the mortality rate can increase to 65% [3].",
            "startOffset": 16937,
            "title": "Background"
        },
        {
            "endOffset": 23933,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0020",
            "sentence": "A dose of 103 TCID50 was used for efficacy testing since that demonstrated uniform disease progression post-challenge.",
            "startOffset": 23815,
            "title": "Viruses"
        },
        {
            "endOffset": 24899,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0030",
            "sentence": "A DNA cassette for MVALassaNP was generated by GeneArt (Thermo Fisher) to contain an orthopoxvirus P11 promotor, Green Fluorescence Protein (GFP) and mH5 promotor followed by an appropriate Kozak sequence upstream of the NP ORF.",
            "startOffset": 24671,
            "title": "Plasmid construction"
        },
        {
            "endOffset": 29786,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0050",
            "sentence": "Plates were developed after 18 h at 37 \u00b0C, 5% CO2 in a humidified incubator.",
            "startOffset": 29710,
            "title": "ELISpot"
        },
        {
            "endOffset": 42945,
            "parents": [],
            "secId": "s0105",
            "sentence": "Elevated IgG responses were demonstrated in all vaccinated mice and the response was further elevated in mice that received a two-dose immunisation regime.",
            "startOffset": 42790,
            "title": "Discussion"
        },
        {
            "endOffset": 48524,
            "parents": [],
            "secId": "s0105",
            "sentence": "In this study the prime and boost vaccinations were homologous to the challenge strain (GA391).",
            "startOffset": 48429,
            "title": "Discussion"
        }
    ],
    "docId": "S0264410X19309144",
    "metadata": {
        "asjc": [
            "1313",
            "2400",
            "2725",
            "2739",
            "3400"
        ],
        "authors": [
            {
                "email": "emma.kennedy@phe.gov.uk",
                "first": "E. M.",
                "initial": "E.M.",
                "last": "Kennedy"
            },
            {
                "email": null,
                "first": "S. D.",
                "initial": "S.D.",
                "last": "Dowall"
            },
            {
                "email": null,
                "first": "F. J.",
                "initial": "F.J.",
                "last": "Salguero"
            },
            {
                "email": null,
                "first": "P.",
                "initial": "P.",
                "last": "Yeates"
            },
            {
                "email": null,
                "first": "M.",
                "initial": "M.",
                "last": "Aram"
            },
            {
                "email": null,
                "first": "R.",
                "initial": "R.",
                "last": "Hewson"
            }
        ],
        "doi": "10.1016/j.vaccine.2019.07.023",
        "firstpage": "5404",
        "issn": "0264410X",
        "keywords": [
            "Efficacy",
            "Immunogenicity",
            "Lassa",
            "Modified Vaccinia Ankara (MVA)",
            "Nucleoprotein",
            "Recombinant vaccine",
            "Vaccine"
        ],
        "lastpage": "5413",
        "openaccess": "Full",
        "pub_year": 2019,
        "subjareas": [
            "BIOC",
            "IMMU",
            "MEDI",
            "VETE"
        ],
        "title": "A vaccine based on recombinant modified Vaccinia Ankara containing the nucleoprotein from Lassa virus protects against disease progression in a guinea pig model"
    }
}